<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:66.0pt;left:57.3pt;line-height:9.5pt"><span style="font-family:Times New Roman,serif;font-size:9.5pt">SYMPOSIUM: CURRENT CONCEPTS IN CERVICAL SPINE SURGERY</span></p>
<p style="top:106.6pt;left:51.0pt;line-height:15.9pt"><span style="font-family:Times New Roman,serif;font-size:15.9pt">Spinal Cord Injury</span></p>
<p style="top:132.5pt;left:51.0pt;line-height:12.0pt"><span style="font-family:Times New Roman,serif;font-size:12.0pt">A Systematic Review of Current Treatment Options</span></p>
<p style="top:163.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">David W. Cadotte MSc, MD,</span></p>
<p style="top:176.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Michael G. Fehlings MD, PhD, FRCSC, FACS</span></p>
<p style="top:244.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Published online: 16 November 2010</span></p>
<p style="top:254.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:AdvPSSym,serif;font-size:8.5pt">&#xfffd;</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> The Association of Bone and Joint Surgeons</span><span style="font-family:AdvPi3,serif;font-size:8.5pt">1</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> 2010</span></p>
<p style="top:282.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Abstract</span></p>
<p style="top:294.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Background</span></p>
<p style="top:294.8pt;left:109.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Spinal cord injury (SCI) is a devastating</span></p>
<p style="top:307.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">event often resulting in permanent neurologic de&#xfb01;cit.</span></p>
<p style="top:319.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Research has revealed an understanding of mechanisms</span></p>
<p style="top:332.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">that occur after the primary injury and contribute to func-</span></p>
<p style="top:344.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tional loss. By targeting these secondary mechanisms of</span></p>
<p style="top:357.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">injury, clinicians may be able to offer improved recovery</span></p>
<p style="top:369.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">after SCI.</span></p>
<p style="top:382.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Questions/purposes</span></p>
<p style="top:382.0pt;left:139.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">In this review, we highlight advances</span></p>
<p style="top:394.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in the &#xfb01;eld of SCI by framing three questions: (1) What is</span></p>
<p style="top:406.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the preclinical evidence for the neuroprotective agent ril-</span></p>
<p style="top:419.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">uzole that has allowed this agent to move into clinical</span></p>
<p style="top:431.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">trials? (2) What is the preclinical evidence for Rho</span></p>
<p style="top:444.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">antagonists that have allowed this group of compounds to</span></p>
<p style="top:456.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">move into clinical trials? (3) What is the evidence for early</span></p>
<p style="top:469.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">surgical decompression after SCI?</span></p>
<p style="top:282.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Methods</span></p>
<p style="top:282.4pt;left:350.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">We</span></p>
<p style="top:282.4pt;left:375.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">conducted</span></p>
<p style="top:282.4pt;left:428.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">a</span></p>
<p style="top:282.4pt;left:443.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">systematic</span></p>
<p style="top:282.4pt;left:497.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">review</span></p>
<p style="top:282.4pt;left:535.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of</span></p>
<p style="top:294.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">MEDLINE and EMBASE-cited articles related to SCI to</span></p>
<p style="top:307.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">address these questions.</span></p>
<p style="top:319.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Results</span></p>
<p style="top:319.8pt;left:345.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">As a result of an improved understanding of the</span></p>
<p style="top:332.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">secondary mechanisms of SCI, speci&#xfb01;c clinical strategies</span></p>
<p style="top:344.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">have been established. We highlight three strategies that</span></p>
<p style="top:357.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">have made their way from bench to bedside: the sodium-</span></p>
<p style="top:369.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">glutamate antagonist riluzole, the Rho inhibitor Cethrin,</span></p>
<p style="top:382.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and early surgical decompression. Each of these modalities</span></p>
<p style="top:394.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">is under clinical investigation. We highlight the funda-</span></p>
<p style="top:406.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mental science that led to this development.</span></p>
<p style="top:419.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Conclusions</span></p>
<p style="top:419.4pt;left:365.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">As our understanding of the fundamental</span></p>
<p style="top:431.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mechanisms of SCI improves, we must keep abreast of</span></p>
<p style="top:444.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">these discoveries to translate them into therapies that will</span></p>
<p style="top:456.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">hopefully bene&#xfb01;t patients. We summarize this process of</span></p>
<p style="top:469.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">bench to bedside with regard to SCI.</span></p>
<p style="top:506.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Introduction</span></p>
<p style="top:531.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Epidemiologic research has demonstrated that spinal cord</span></p>
<p style="top:543.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">injury (SCI) affects 10 to 40 persons per million popu-</span></p>
<p style="top:556.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lation per annum in developed countries such as the</span></p>
<p style="top:568.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">United States [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">53</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. This number must be interpreted with</span></p>
<p style="top:581.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reference to a complete picture of this devastating con-</span></p>
<p style="top:593.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">dition: a substantial number of individuals who sustain a</span></p>
<p style="top:606.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">SCI die before reaching the hospital; patients who do</span></p>
<p style="top:618.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reach the hospital have complications related to their</span></p>
<p style="top:631.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">injury and are at high risk of morbidity and mortality;</span></p>
<p style="top:643.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the economic costs of this injury are estimated in the</span></p>
<p style="top:655.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">billions of dollars in developed countries (United States);</span></p>
<p style="top:668.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and the personal and family suffering is incalculable</span></p>
<p style="top:680.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">[</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">2</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 29</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 54</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. Those sustaining SCI tend to be either young</span></p>
<p style="top:693.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">individuals sustaining traumatic injury at the prime of</span></p>
<p style="top:705.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">their personal lives and economic earning potential or</span></p>
<p style="top:507.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">One of the authors (MGF) is the principal investigator on clinical</span></p>
<p style="top:517.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">trials investigating the use of riluzole and Cethrin in spinal cord</span></p>
<p style="top:527.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">injury, which are funded by the Christopher and Dana Reeve Paralysis</span></p>
<p style="top:537.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Foundation and Alseres Pharmaceuticals, respectively; and is also</span></p>
<p style="top:547.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Principal Investigator on the STASCIS trial, which is supported by</span></p>
<p style="top:557.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">the Spine Trauma Study Group through grants from Medtronic.</span></p>
<p style="top:578.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Electronic supplementary material</span></p>
<p style="top:578.4pt;left:188.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">The online version of this</span></p>
<p style="top:587.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">article (doi:</span><span style="font-family:Times New Roman,serif;font-size:8.5pt;color:#0000ff">10.1007/s11999-010-1674-0</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">) contains supplementary</span></p>
<p style="top:596.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">material, which is available to authorized users.</span></p>
<p style="top:617.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">D. W. Cadotte, M. G. Fehlings</span></p>
<p style="top:627.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Division of Neurosurgery, University of Toronto,</span></p>
<p style="top:637.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Toronto, ON, Canada</span></p>
<p style="top:657.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">M. G. Fehlings (</span><span style="font-family:AdvPSSPS,serif;font-size:8.5pt">&amp;</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">)</span></p>
<p style="top:667.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Neural Repair and Regeneration, Spinal Program,</span></p>
<p style="top:677.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">University Health Network, Toronto Western Hospital,</span></p>
<p style="top:687.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">McLaughlin Pavilion, 12th Floor, Room 407,</span></p>
<p style="top:697.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">399 Bathurst Street, Toronto, ON M5T 2S8, Canada</span></p>
<p style="top:707.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">e-mail: michael.fehlings@uhn.on.ca</span></p>
<p style="top:733.4pt;left:52.4pt;line-height:14.9pt"><span style="font-family:AdvSPRING,serif;font-size:14.9pt">123</span></p>
<p style="top:33.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Clin Orthop Relat Res (2011) 469:732&#x2013;741</span></p>
<p style="top:44.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">DOI 10.1007/s11999-010-1674-0</span></p>


<p style="top:58.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">older individuals who sustain falls. In either case, the</span></p>
<p style="top:70.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">consequence of neurologic injury is overwhelming and</span></p>
<p style="top:83.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">has prompted intense research to understand the patho-</span></p>
<p style="top:95.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">physiological mechanisms and discover potential thera-</span></p>
<p style="top:108.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">peutic strategies.</span></p>
<p style="top:120.6pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">At the root of such strategies is a clear understanding of</span></p>
<p style="top:133.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the secondary mechanisms of SCI and its distinction from</span></p>
<p style="top:145.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">primary injury. Primary SCI refers to damage to the neural</span></p>
<p style="top:157.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">elements sustained at the time of trauma. This can take the</span></p>
<p style="top:170.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">form of shear forces to axons or blood vessels and results</span></p>
<p style="top:182.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in, to date, irreversible injury. Secondary SCI refers to the</span></p>
<p style="top:195.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">body&#x2019;s response to primary injury. A host of cellular cas-</span></p>
<p style="top:207.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cades has been identi&#xfb01;ed that occurs immediately after</span></p>
<p style="top:220.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">injury and may persist for months to years. These events,</span></p>
<p style="top:232.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">although integral to the normal cellular machinery, have</span></p>
<p style="top:245.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">been demonstrated to exacerbate underlying injury and</span></p>
<p style="top:257.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">prevent neurologic recovery. By detailing these cascades,</span></p>
<p style="top:270.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">researchers have established speci&#xfb01;c targets that may mit-</span></p>
<p style="top:282.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">igate secondary SCI and have the potential to improve</span></p>
<p style="top:294.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">patient outcomes. With this foundation, advances have</span></p>
<p style="top:307.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">been made in both nonoperative and operative treatment</span></p>
<p style="top:319.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">strategies. In the paragraphs that follow, we introduce</span></p>
<p style="top:332.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">treatment options for SCI that have received recent atten-</span></p>
<p style="top:344.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion. After this brief introduction, we systematically review</span></p>
<p style="top:357.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the literature for each of these treatments.</span></p>
<p style="top:369.6pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Riluzole is a sodium channel-blocking agent that is</span></p>
<p style="top:382.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">approved for use in persons with amyotrophic lateral</span></p>
<p style="top:394.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sclerosis (ALS). It is reported to have neuroprotective</span></p>
<p style="top:407.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">properties by blocking voltage-sensitive sodium channels</span></p>
<p style="top:419.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">whose persistent activation (excitotoxicity) has been dem-</span></p>
<p style="top:431.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">onstrated to have deleterious effects on neural tissue.</span></p>
<p style="top:444.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">In addition, riluzole antagonizes presynaptic calcium-</span></p>
<p style="top:456.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">dependent glutamate release, a mechanism that may also</span></p>
<p style="top:469.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reduce the deleterious effects of excitotoxicity.</span></p>
<p style="top:481.7pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Rho antagonists act at the level of the neuronal growth</span></p>
<p style="top:494.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cone and play a role in preventing neuronal apoptosis. It is</span></p>
<p style="top:506.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">believed that by preventing an apoptotic fate in the setting</span></p>
<p style="top:519.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of SCI, one may be able to promote axonal sprouting and</span></p>
<p style="top:531.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">regeneration.</span></p>
<p style="top:544.0pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Early surgical decompression after SCI has been a</span></p>
<p style="top:556.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">proposed treatment for a number of years with its funda-</span></p>
<p style="top:568.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mental principle resting in the notion damaged neural</span></p>
<p style="top:581.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tissue has a propensity to swell, and when the tissue swells</span></p>
<p style="top:593.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in a con&#xfb01;ned space, ischemic and excitotoxic mechanisms</span></p>
<p style="top:606.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">are left uncontrolled.</span></p>
<p style="top:618.7pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">In this systematic review, we highlight some of the</span></p>
<p style="top:631.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">recent developments in the treatment of SCI. Speci&#xfb01;cally,</span></p>
<p style="top:643.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">we have formulated three questions whose evidence stems</span></p>
<p style="top:656.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">from preclinical and clinical literature: (1) What is the</span></p>
<p style="top:668.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">preclinical evidence for the neuroprotective agent riluzole</span></p>
<p style="top:680.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">that has allowed this agent to move into clinical trials?</span></p>
<p style="top:693.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(2) What is the preclinical evidence for Rho antagonists</span></p>
<p style="top:705.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">that have allowed this group of compounds to move into</span></p>
<p style="top:58.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">clinical trials? (3) What is the evidence for early surgical</span></p>
<p style="top:70.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">decompression after SCI?</span></p>
<p style="top:108.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Search Strategy and Criteria</span></p>
<p style="top:133.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">This systematic review aims to address the most recent</span></p>
<p style="top:145.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">topics in the treatment of acute traumatic SCI as framed in</span></p>
<p style="top:157.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the three questions listed. As such, we have outlined a</span></p>
<p style="top:170.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">general search strategy along with individual key words</span></p>
<p style="top:182.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and operators for each question.</span></p>
<p style="top:195.3pt;left:317.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Using the OVID interface, we queried the MEDLINE</span></p>
<p style="top:207.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">database (1950 to May Week 1, 2010) and the EMBASE</span></p>
<p style="top:220.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">database (1980 to 2010, Week 19). We included all original</span></p>
<p style="top:232.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">research papers in the English language. We excluded all</span></p>
<p style="top:245.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">clinical case reports, in vitro experiments, photochemically</span></p>
<p style="top:257.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">induced injury models, and nerve root or peripheral ner-</span></p>
<p style="top:270.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">vous system injury models. Lastly, we read all review</span></p>
<p style="top:282.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">articles to ensure that we captured relevant papers but did</span></p>
<p style="top:294.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">not include the review papers themselves in the results.</span></p>
<p style="top:307.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">After articles were chosen (based on the inclusion and</span></p>
<p style="top:319.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">exclusion criteria and key words listed subsequently), we</span></p>
<p style="top:332.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">applied the Downs and Black criteria to assess the meth-</span></p>
<p style="top:344.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">odological quality of each study (see subsequently).</span></p>
<p style="top:357.2pt;left:317.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">For Question 1 we queried &#x2018;&#x2018;riluzole&#x2019;&#x2019; AND &#x2018;&#x2018;spinal cord</span></p>
<p style="top:369.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">injury.&#x2019;&#x2019; This search returned 69 results. With application</span></p>
<p style="top:382.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of our inclusion/exclusion criteria and eliminating irrele-</span></p>
<p style="top:394.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">vant articles, we were left with eight studies. Review</span></p>
<p style="top:406.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">articles provided no additional references.</span></p>
<p style="top:419.4pt;left:317.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">For Question 2 we queried &#x2018;&#x2018;Rho&#x2019;&#x2019; AND &#x2018;&#x2018;antagonist&#x2019;&#x2019;</span></p>
<p style="top:431.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">AND &#x2018;&#x2018;spinal cord injury.&#x2019;&#x2019; This search returned nine</span></p>
<p style="top:444.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">results. With application of our inclusion/exclusion criteria</span></p>
<p style="top:456.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and eliminating irrelevant articles, we were left with six</span></p>
<p style="top:469.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies. Review articles provided an additional three arti-</span></p>
<p style="top:481.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cles that were not captured by our original search, bringing</span></p>
<p style="top:494.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the total to nine studies.</span></p>
<p style="top:506.6pt;left:317.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">For Question 3 we queried &#x2018;&#x2018;timing&#x2019;&#x2019; AND &#x2018;&#x2018;decom-</span></p>
<p style="top:519.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pression&#x2019;&#x2019; AND &#x2018;&#x2018;spinal cord injury.&#x2019;&#x2019; This search strategy</span></p>
<p style="top:531.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">revealed 66 results. With application of our inclusion/</span></p>
<p style="top:544.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">exclusion criteria and eliminating irrelevant articles, we</span></p>
<p style="top:556.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">were left with 38 studies. Review articles provided an</span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">additional three articles that were not captured by our</span></p>
<p style="top:581.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">original search bringing the total to 41 studies (19 pre-</span></p>
<p style="top:593.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">clinical and 22 clinical studies).</span></p>
<p style="top:606.2pt;left:317.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Clinical</span></p>
<p style="top:606.2pt;left:357.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies</span></p>
<p style="top:606.2pt;left:393.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">were</span></p>
<p style="top:606.2pt;left:420.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">assessed</span></p>
<p style="top:606.2pt;left:462.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">for</span></p>
<p style="top:606.2pt;left:481.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">methodological</span></p>
<p style="top:618.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">quality using the Downs and Black criteria [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">23</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. Their</span></p>
<p style="top:631.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">27-item quality assessment checklist evaluates the quality</span></p>
<p style="top:643.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of reporting, external validity, internal validity (bias and</span></p>
<p style="top:656.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">confounding), and power with a maximal quality index</span></p>
<p style="top:668.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(QI) of 32. Quality scores were presented as proportions of</span></p>
<p style="top:680.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the total possible score (ie, 32) of the quality assessment</span></p>
<p style="top:693.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">scale (where 100% represents the maximum quality).</span></p>
<p style="top:705.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Studies were not excluded based on the quality of methods.</span></p>
<p style="top:33.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Volume 469, Number 3, March 2011</span></p>
<p style="top:33.2pt;left:356.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">SCI: Treatment Options for Spinal Cord Injury</span></p>
<p style="top:33.2pt;left:531.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">733</span></p>
<p style="top:733.4pt;left:504.6pt;line-height:14.9pt"><span style="font-family:AdvSPRING,serif;font-size:14.9pt">123</span></p>


<p style="top:58.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Both authors (DWC, MGF) reviewed the clinical studies</span></p>
<p style="top:70.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">independently for quality. Disagreements were resolved by</span></p>
<p style="top:83.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">discussion and consensus between the two authors.</span></p>
<p style="top:120.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Results</span></p>
<p style="top:145.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Question 1</span></p>
<p style="top:170.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Recent advances in our understanding of the pathobiology</span></p>
<p style="top:182.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of SCI continue to drive the development of new thera-</span></p>
<p style="top:195.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">peutic agents and clinical strategies. The neuroprotective</span></p>
<p style="top:207.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">agent riluzole, currently in use to treat patients with ALS,</span></p>
<p style="top:58.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">has been the focus of eight preclinical studies (Table</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 1</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">)</span></p>
<p style="top:70.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">[</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">3</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 33</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 39</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 43</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 44</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 53</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 55</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 56</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. Its neuroprotective properties</span></p>
<p style="top:83.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">are the result of blocking voltage-sensitive sodium chan-</span></p>
<p style="top:95.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nels and antagonism of presynaptic calcium-dependent</span></p>
<p style="top:108.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">glutamate release. Each of these investigations has been</span></p>
<p style="top:120.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">carried out in a rat model of SCI that used the following</span></p>
<p style="top:133.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">outcome measures: nonbehavioral: tissue-sparing, reduced</span></p>
<p style="top:145.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">MAP-2 loss (MAP-2 is a microtubule-associated protein</span></p>
<p style="top:157.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">that decreased lipid peroxidation and improved electro-</span></p>
<p style="top:170.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">physiological recordings); behavioral: improved locomotor</span></p>
<p style="top:182.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">scores (BBB) and improved performance on inclined plane</span></p>
<p style="top:195.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">testing. A single study investigated spasticity. Seven of</span></p>
<p style="top:207.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">eight studies reported on nonbehavioral outcome measures.</span></p>
<p style="top:246.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Table 1.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> A summary of preclinical animal literature studying the effect of the neuroprotective agent riluzole in spinal cord injury</span></p>
<p style="top:263.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Reference</span></p>
<p style="top:263.2pt;left:116.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Species Injury model</span></p>
<p style="top:263.2pt;left:215.8pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Riluzole dose and route of delivery</span></p>
<p style="top:263.2pt;left:364.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Reported outcomes</span></p>
<p style="top:281.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Stutzmann et al.,</span></p>
<p style="top:291.9pt;left:59.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1996 [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt;color:#0000ff">56</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">]</span></p>
<p style="top:281.9pt;left:116.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rat</span></p>
<p style="top:281.9pt;left:148.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Thoracic</span></p>
<p style="top:291.9pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">compression</span></p>
<p style="top:301.9pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">with Fogarty</span></p>
<p style="top:311.8pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">catheter</span></p>
<p style="top:281.9pt;left:215.8pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2 mg/kg IV administered 30 minutes after</span></p>
<p style="top:291.9pt;left:224.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">injury and twice daily for 10 days</span></p>
<p style="top:281.9pt;left:364.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Riluzole decreased the amount of necrosis in the</span></p>
<p style="top:291.9pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">gray and white matter; riluzole-treated animals</span></p>
<p style="top:301.9pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">recovered SSEPs (amplitude, duration, and</span></p>
<p style="top:311.8pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">latency), whereas control animals did not; in</span></p>
<p style="top:321.8pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">terms of behavior, treated animals were able</span></p>
<p style="top:331.7pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">to sit upright (using paws), whereas control</span></p>
<p style="top:341.7pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">animals were not</span></p>
<p style="top:354.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Springer et al.,</span></p>
<p style="top:364.4pt;left:59.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1997 [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt;color:#0000ff">55</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">]</span></p>
<p style="top:354.5pt;left:116.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rat</span></p>
<p style="top:354.5pt;left:148.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Thoracic</span></p>
<p style="top:364.4pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">impactor</span></p>
<p style="top:354.5pt;left:215.8pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">8 mg/kg IP administered 15 minutes</span></p>
<p style="top:364.4pt;left:224.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">before injury and 2 hours after injury</span></p>
<p style="top:354.5pt;left:364.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Behavioral outcomes not reported; riluzole</span></p>
<p style="top:364.4pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">decreased the amount of MAP-2</span></p>
<p style="top:374.4pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">(microtubule-associated protein) loss after SCI</span></p>
<p style="top:387.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Mu et al.,</span></p>
<p style="top:397.1pt;left:59.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2000 [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt;color:#0000ff">44</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">]</span></p>
<p style="top:387.1pt;left:116.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rat</span></p>
<p style="top:387.1pt;left:148.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Thoracic</span></p>
<p style="top:397.1pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">impactor</span></p>
<p style="top:387.1pt;left:215.8pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">8 mg/kg IP administered 2 hours and</span></p>
<p style="top:397.1pt;left:224.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">4 hours after injury and then daily</span></p>
<p style="top:407.1pt;left:224.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">for 7 days</span></p>
<p style="top:387.1pt;left:364.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Riluzole alone did not affect spinal cord cavitation;</span></p>
<p style="top:397.1pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">however, when combined with</span></p>
<p style="top:407.1pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">methylprednisolone, the combination resulted in</span></p>
<p style="top:417.0pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">decreased spinal cord cavitation; similarly, only</span></p>
<p style="top:427.0pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">the combination was able to improve locomotor</span></p>
<p style="top:437.0pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">scores</span></p>
<p style="top:449.7pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Mu et al.,</span></p>
<p style="top:459.6pt;left:59.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2000 [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt;color:#0000ff">43</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">]</span></p>
<p style="top:449.7pt;left:116.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rat</span></p>
<p style="top:449.7pt;left:148.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Thoracic</span></p>
<p style="top:459.6pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">impactor</span></p>
<p style="top:449.7pt;left:215.8pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">8 mg/kg IP administered 15 minutes</span></p>
<p style="top:459.6pt;left:224.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">and 2 hours after injury</span></p>
<p style="top:449.7pt;left:364.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Behavioral outcomes not investigated; riluzole</span></p>
<p style="top:459.6pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">treatment resulted in improved mitochondrial</span></p>
<p style="top:469.6pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">function and enhanced glutamate and glucose</span></p>
<p style="top:479.6pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">uptake; lipid peroxidation was decreased with</span></p>
<p style="top:489.6pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">riluzole</span></p>
<p style="top:502.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Schwartz and</span></p>
<p style="top:512.3pt;left:59.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Fehlings,</span></p>
<p style="top:522.2pt;left:59.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2001 [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt;color:#0000ff">53</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">]</span></p>
<p style="top:502.3pt;left:116.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rat</span></p>
<p style="top:502.3pt;left:148.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Cervicothoracic</span></p>
<p style="top:512.3pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">clip</span></p>
<p style="top:522.2pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">compression</span></p>
<p style="top:502.3pt;left:215.8pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">5 mg/kg IP administered at the time of</span></p>
<p style="top:512.3pt;left:224.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">injury; *note: authors compare other</span></p>
<p style="top:522.2pt;left:224.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">neuroprotective agents (see reference</span></p>
<p style="top:532.2pt;left:224.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">for details)</span></p>
<p style="top:502.3pt;left:364.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Riluzole resulted in greater retrograde labeled</span></p>
<p style="top:512.3pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">neurons in the brain stem (especially red nucleus);</span></p>
<p style="top:522.2pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">there was also reduced cavitation in riluzole-</span></p>
<p style="top:532.2pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">treated animals; riluzole also improved locomotor</span></p>
<p style="top:542.1pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">scores and incline plane testing</span></p>
<p style="top:554.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">McAdoo et al.,</span></p>
<p style="top:564.9pt;left:59.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2005 [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt;color:#0000ff">39</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">]</span></p>
<p style="top:554.9pt;left:116.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rat</span></p>
<p style="top:554.9pt;left:148.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Thoracic</span></p>
<p style="top:564.9pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">impactor</span></p>
<p style="top:554.9pt;left:215.8pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2 mM administered through microdialysis</span></p>
<p style="top:564.9pt;left:224.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#xfb01;ber at the time of injury; *note:</span></p>
<p style="top:574.8pt;left:224.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">authors compare other neuroprotective</span></p>
<p style="top:584.8pt;left:224.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">agents (see reference for details)</span></p>
<p style="top:554.9pt;left:364.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Behavioral outcomes not investigated; riluzole did</span></p>
<p style="top:564.9pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">not decrease glutamate release after SCI</span></p>
<p style="top:597.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Ates et al.,</span></p>
<p style="top:607.5pt;left:59.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2007 [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt;color:#0000ff">3</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">]</span></p>
<p style="top:597.5pt;left:116.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rat</span></p>
<p style="top:597.5pt;left:148.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Thoracic</span></p>
<p style="top:607.5pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">contusion</span></p>
<p style="top:617.5pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">(weight drop)</span></p>
<p style="top:597.5pt;left:215.8pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">8 mg/kg IP administered at the time of</span></p>
<p style="top:607.5pt;left:224.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">injury; *note: authors compare other</span></p>
<p style="top:617.5pt;left:224.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">neuroprotective agents (see reference</span></p>
<p style="top:627.5pt;left:224.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">for details)</span></p>
<p style="top:597.5pt;left:364.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Riluzole resulted in greater myelin and neuronal</span></p>
<p style="top:607.5pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">gray matter sparing and smaller lesion area in</span></p>
<p style="top:617.5pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">comparison to controls; both motor function</span></p>
<p style="top:627.5pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">scores and inclined plane angles were improved</span></p>
<p style="top:637.4pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">with riluzole</span></p>
<p style="top:650.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Kitzman,</span></p>
<p style="top:660.1pt;left:59.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2009 [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt;color:#0000ff">33</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">]</span></p>
<p style="top:650.1pt;left:116.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rat</span></p>
<p style="top:650.1pt;left:148.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Sacral cord</span></p>
<p style="top:660.1pt;left:156.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">transection</span></p>
<p style="top:650.1pt;left:215.8pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">8 mg/kg IP administered at 4 weeks</span></p>
<p style="top:660.1pt;left:224.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">after injury and then daily for 3 days;</span></p>
<p style="top:670.1pt;left:224.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">10 mg/kg IP administered at 4 weeks</span></p>
<p style="top:680.1pt;left:224.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">after injury and then daily for 3 days</span></p>
<p style="top:650.1pt;left:364.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Only behavioral outcomes; 8 mg/kg resulted in</span></p>
<p style="top:660.1pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">diminished tail spasticity; 10 mg/kg also resulted</span></p>
<p style="top:670.1pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">in diminished spasticity but also resulted in</span></p>
<p style="top:680.1pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">lethargy and locomotor ataxia in two of three</span></p>
<p style="top:690.0pt;left:373.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">animals</span></p>
<p style="top:706.7pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">IV</span><span style="font-family:AdvTir_symb,serif;font-size:8.5pt"> =</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> intravenous; IP</span><span style="font-family:AdvTir_symb,serif;font-size:8.5pt"> =</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> intraperitoneal; SSEP</span><span style="font-family:AdvTir_symb,serif;font-size:8.5pt"> =</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> somatosensory-evoked potential; SCI</span><span style="font-family:AdvTir_symb,serif;font-size:8.5pt"> =</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> spinal cord injury.</span></p>
<p style="top:33.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">734</span></p>
<p style="top:33.2pt;left:75.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Cadotte and Fehlings</span></p>
<p style="top:33.2pt;left:384.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Clinical Orthopaedics and Related Research</span><sup><span style="font-family:AdvPi3,serif;font-size:6.0pt">1</span></sup></p>
<p style="top:733.4pt;left:52.4pt;line-height:14.9pt"><span style="font-family:AdvSPRING,serif;font-size:14.9pt">123</span></p>


<p style="top:58.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Ates et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">3</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] report greater myelin and neuronal gray</span></p>
<p style="top:70.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">matter-sparing and overall smaller lesion areas in riluzole-</span></p>
<p style="top:83.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">treated animals. Using retrograde labeling and cell count-</span></p>
<p style="top:95.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ing techniques, Schwartz and Fehlings [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">53</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] reported</span></p>
<p style="top:108.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">greater numbers of neurons after injury in riluzole-treated</span></p>
<p style="top:120.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">animals. With regard to oxidative stress, Mu and col-</span></p>
<p style="top:133.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">leagues [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">43</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] report that riluzole in combination with</span></p>
<p style="top:145.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">methylprednisolone improves mitochondrial function and</span></p>
<p style="top:157.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">enhances glutamate uptake. The same group reports</span></p>
<p style="top:170.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">increased</span></p>
<p style="top:170.4pt;left:97.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">spared</span></p>
<p style="top:170.4pt;left:132.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tissue</span></p>
<p style="top:170.4pt;left:163.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">rather</span></p>
<p style="top:170.4pt;left:195.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">than</span></p>
<p style="top:170.4pt;left:221.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cavitation</span></p>
<p style="top:170.4pt;left:270.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">[</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">44</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">].</span></p>
<p style="top:182.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Stutzmann et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">56</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] report a combination of less white</span></p>
<p style="top:195.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">matter hemorrhage and improved somatosensory-evoked</span></p>
<p style="top:207.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">potentials in riluzole-treated animals over controls. The</span></p>
<p style="top:220.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">only negative study, reported by McAdoo et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">39</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">],</span></p>
<p style="top:232.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">demonstrated that riluzole had no direct effect on glutamate</span></p>
<p style="top:245.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">release as measured by microdialysis. In terms of behav-</span></p>
<p style="top:257.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ioral outcomes, &#xfb01;ve of eight studies reported this metric</span></p>
<p style="top:270.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with mixed results [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">3</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 33</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 43</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 53</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 56</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. Riluzole was</span></p>
<p style="top:282.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reported to demonstrate improved BBB scores and/or</span></p>
<p style="top:294.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">inclined plane angles in three studies [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">3</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 43</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 53</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. Mu et al.</span></p>
<p style="top:307.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">[</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">43</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] only report an improvement in behavioral scores with</span></p>
<p style="top:319.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the addition of methylprednisolone. Finally, Kitzman</span></p>
<p style="top:332.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reported transient improvement in spasticity [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">33</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">].</span></p>
<p style="top:369.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Question 2</span></p>
<p style="top:394.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Rho antagonists (Cethrin is the commercial form currently</span></p>
<p style="top:407.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">available) are speci&#xfb01;c inhibitors of Rho, a signaling mol-</span></p>
<p style="top:419.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ecule for myelin and extracellular matrix inhibitors of</span></p>
<p style="top:431.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">regeneration. This compound is directly applied to the dura</span></p>
<p style="top:444.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">at the time of surgery after injury. In our systematic review</span></p>
<p style="top:456.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">we identi&#xfb01;ed nine preclinical studies that examined the</span></p>
<p style="top:469.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">effect of Rho antagonists in the setting of SCI [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">12</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 20</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 24</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span></p>
<p style="top:481.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">26</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 38</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 46</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 57</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 58</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 63</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. These investigations made use of a</span></p>
<p style="top:494.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">combination of mouse and rat models consisting of dorsal</span></p>
<p style="top:506.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">hemisection, impactor injury, transection, and hemisection</span></p>
<p style="top:519.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(Table</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 2</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">). Outcome measures in these studies can be</span></p>
<p style="top:531.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">classi&#xfb01;ed into nonbehavioral (histologic, biochemical, and</span></p>
<p style="top:544.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">physiological) and behavioral (locomotor function as</span></p>
<p style="top:556.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">measured by the BBB test). In addition, a number of</span></p>
<p style="top:568.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies compared immediate treatment (within minutes of</span></p>
<p style="top:581.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">SCI) or delayed treatment (usually weeks after SCI).</span></p>
<p style="top:593.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Dubreuil et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">24</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] provided fundamental proof that</span></p>
<p style="top:606.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">endogenous cells within a damaged spinal cord are able to</span></p>
<p style="top:618.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">take up and retain the rho antagonist C3 transferase (termed</span></p>
<p style="top:631.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Cethrin in human clinical trials). The outcome of other</span></p>
<p style="top:643.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nonbehavioral investigations can be broadly summarized</span></p>
<p style="top:656.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">into those that demonstrate a change in the amount of</span></p>
<p style="top:668.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">damaged tissue and those that demonstrate increased</span></p>
<p style="top:680.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sprouting of cell populations and those that affect axonal</span></p>
<p style="top:693.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">growth. Five of nine studies report directly on the extent of</span></p>
<p style="top:705.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">damaged tissue, each showing reduced spinal cord lesion</span></p>
<p style="top:58.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">after induced trauma [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">26</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 38</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 57</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 58</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 63</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. Yamagishi et al.</span></p>
<p style="top:70.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">further classi&#xfb01;ed the change as reducing microtubule and</span></p>
<p style="top:83.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neuro&#xfb01;lament breakdown suggesting delayed Wallerian</span></p>
<p style="top:95.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">degeneration in treated animals [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">63</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. Most recently, Lord-</span></p>
<p style="top:108.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Fontaine et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">38</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] showed reduced lesion extent combined</span></p>
<p style="top:120.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with increased spared white matter tracts. Three studies</span></p>
<p style="top:133.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">comment on neuronal sprouting: Nishio et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">46</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] report</span></p>
<p style="top:145.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sprouting of corticospinal neurons with immediate appli-</span></p>
<p style="top:157.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cation of Fasudil (another form of a Rho kinase inhibitor)</span></p>
<p style="top:170.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">but not delayed treatment. Similarly, Tanaka et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">58</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]</span></p>
<p style="top:182.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">report that three different Rho kinase inhibitors (Y-27632,</span></p>
<p style="top:195.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">HA-1077, and GST-</span><span style="font-family:AdvPSMP13,serif;font-size:10.0pt">D</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">NLS-p21-PTD-myc protein) led to</span></p>
<p style="top:207.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">substantial sprouting. Fournier et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">26</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] report that C3</span></p>
<p style="top:220.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">transferase has no effect on sprouting. Lastly, there were</span></p>
<p style="top:232.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">two studies that demonstrate axonal regeneration [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">12</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 20</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]</span></p>
<p style="top:245.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and a single study that showed no effect on regeneration of</span></p>
<p style="top:257.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">injured axons [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">26</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">].</span></p>
<p style="top:270.0pt;left:317.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Seven of nine studies reported on behavioral outcomes.</span></p>
<p style="top:282.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">The results are mixed with the majority of research groups</span></p>
<p style="top:294.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">reporting</span></p>
<p style="top:294.9pt;left:350.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">improved</span></p>
<p style="top:294.9pt;left:397.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">locomotor</span></p>
<p style="top:294.9pt;left:446.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ability</span></p>
<p style="top:294.9pt;left:480.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with</span></p>
<p style="top:294.9pt;left:506.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">treatment</span></p>
<p style="top:307.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of</span></p>
<p style="top:307.4pt;left:323.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Rho</span></p>
<p style="top:307.4pt;left:348.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">kinase</span></p>
<p style="top:307.4pt;left:383.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">inhibitors.</span></p>
<p style="top:307.4pt;left:432.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Of</span></p>
<p style="top:307.4pt;left:451.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the</span></p>
<p style="top:307.4pt;left:472.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">negative</span></p>
<p style="top:307.4pt;left:515.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">results,</span></p>
<p style="top:319.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">C3-transferase was associated with three severely emaci-</span></p>
<p style="top:332.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ated rats with a poor behavioral response [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">57</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] and low-dose</span></p>
<p style="top:344.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Y27632 was associated with worse neurologic recovery</span></p>
<p style="top:357.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">[</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">12</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. When given at high doses, Y27632 resulted in</span></p>
<p style="top:369.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">improved neurologic outcomes compared with controls</span></p>
<p style="top:382.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">[</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">12</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. This positive result was echoed by the majority</span></p>
<p style="top:394.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of available studies with the following observations:</span></p>
<p style="top:407.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(1) behavioral improvements tend to appear weeks after</span></p>
<p style="top:419.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">drug delivery [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">26</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 38</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]; (2) immediate treatment results in</span></p>
<p style="top:431.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">improved outcomes but not delayed treatment [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">46</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]; and</span></p>
<p style="top:444.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(3) improvements in behavioral outcomes occur with dif-</span></p>
<p style="top:456.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ferent Rho antagonists (C3 transferase, Y-27632, HA-1077,</span></p>
<p style="top:469.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and GST-</span><span style="font-family:AdvPSMP13,serif;font-size:10.0pt">D</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">NLS-p21-PTD-myc protein) [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">20</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 58</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. In sum-</span></p>
<p style="top:481.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">mary, there is substantial evidence both in terms of</span></p>
<p style="top:494.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nonbehavioral outcomes and behavioral outcomes for the</span></p>
<p style="top:506.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">use of Rho antagonists after SCI.</span></p>
<p style="top:544.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Question 3</span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Surgical decompression after SCI is founded on a solid</span></p>
<p style="top:581.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">basis of animal studies demonstrating improved neurologic</span></p>
<p style="top:593.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">outcomes with early decompression. Not surprisingly,</span></p>
<p style="top:606.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">human clinical trials, and the complexity of caring for</span></p>
<p style="top:618.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">acutely injured patients, have been less convincing.</span></p>
<p style="top:631.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">We systematically identi&#xfb01;ed 19 preclinical studies and</span></p>
<p style="top:643.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">22 clinical studies that address the question of early sur-</span></p>
<p style="top:656.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">gical decompression after SCI. (Supplemental materials are</span></p>
<p style="top:668.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">available with the online version of CORR.) The timing of</span></p>
<p style="top:680.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">decompression in animal models ranges from minutes</span></p>
<p style="top:693.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">through the 24-hour mark with earlier decompression</span></p>
<p style="top:705.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">usually associated with greater neurologic improvement.</span></p>
<p style="top:33.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Volume 469, Number 3, March 2011</span></p>
<p style="top:33.2pt;left:356.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">SCI: Treatment Options for Spinal Cord Injury</span></p>
<p style="top:33.2pt;left:531.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">735</span></p>
<p style="top:733.4pt;left:504.6pt;line-height:14.9pt"><span style="font-family:AdvSPRING,serif;font-size:14.9pt">123</span></p>


<p style="top:707.0pt;left:63.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Table 2.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> A summary of preclinical animal literature studying the effect of Rho antagonists in spinal cord injury</span></p>
<p style="top:707.0pt;left:80.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Reference</span></p>
<p style="top:585.0pt;left:80.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Species</span></p>
<p style="top:534.8pt;left:80.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Injury model</span></p>
<p style="top:401.2pt;left:80.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rho antagonist applied (directly</span></p>
<p style="top:401.2pt;left:90.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">applied unless otherwise stated)</span></p>
<p style="top:255.7pt;left:80.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Reported outcomes</span></p>
<p style="top:707.0pt;left:108.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Dergham et al., 2002 [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt;color:#0000ff">20</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">]</span></p>
<p style="top:585.0pt;left:108.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Mouse</span></p>
<p style="top:534.8pt;left:108.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Thoracic hemisection</span></p>
<p style="top:401.2pt;left:108.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1) C3 transferase</span></p>
<p style="top:401.2pt;left:121.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2) Y27632</span></p>
<p style="top:255.7pt;left:108.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Axons regenerating over long distances show upregulation</span></p>
<p style="top:247.3pt;left:118.8pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">of GAP-43 mRNA; locomotor function improved within</span></p>
<p style="top:247.3pt;left:128.8pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">24 hours of injury in comparison to controls</span></p>
<p style="top:707.0pt;left:141.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Sung et al., 2003 [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt;color:#0000ff">57</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">]</span></p>
<p style="top:585.0pt;left:141.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rat</span></p>
<p style="top:534.8pt;left:141.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Thoracic impactor</span></p>
<p style="top:401.2pt;left:141.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1) C3 transferase</span></p>
<p style="top:401.2pt;left:154.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2) Y27632 (oral)</span></p>
<p style="top:401.2pt;left:167.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">3) Fasudil</span></p>
<p style="top:255.7pt;left:141.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">The extent of tissue damage at 5 weeks was reduced in</span></p>
<p style="top:247.3pt;left:151.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">treated animals; the experiment had to be terminated</span></p>
<p style="top:247.3pt;left:161.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">early in three rats 1 week after injury as a result of</span></p>
<p style="top:247.3pt;left:171.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">emaciation (C3 transferase); rats receiving fasudil</span></p>
<p style="top:247.3pt;left:181.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">showed improved locomotor function, whereas rats</span></p>
<p style="top:247.3pt;left:191.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">receiving Y-27632 did not</span></p>
<p style="top:707.0pt;left:204.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Fournier et al., 2003 [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt;color:#0000ff">26</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">]</span></p>
<p style="top:585.0pt;left:204.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rat</span></p>
<p style="top:534.8pt;left:204.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Thoracic hemisection</span></p>
<p style="top:401.2pt;left:204.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1) C3 transferase</span></p>
<p style="top:401.2pt;left:216.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2) Y27632</span></p>
<p style="top:255.7pt;left:204.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">C3 transferase did not promote axonal sprouting or</span></p>
<p style="top:247.3pt;left:214.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">regeneration but did reduce the amount of scar tissue;</span></p>
<p style="top:247.3pt;left:224.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Y-27632 did enhance the spouting of corticospinal tract</span></p>
<p style="top:247.3pt;left:234.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">&#xfb01;bers; locomotor scores in both C3-transferase and</span></p>
<p style="top:247.3pt;left:244.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Y-27632 animals were improved</span></p>
<p style="top:707.0pt;left:256.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Dubreuil et al., 2003 [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt;color:#0000ff">24</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">]</span></p>
<p style="top:585.0pt;left:256.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rat/mouse</span></p>
<p style="top:534.8pt;left:256.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rat: thoracic hemisection or</span></p>
<p style="top:526.3pt;left:266.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">thoracic impactor</span></p>
<p style="top:534.8pt;left:279.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Mouse: thoracic hemisection</span></p>
<p style="top:401.2pt;left:256.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1) C3 transferase</span></p>
<p style="top:255.7pt;left:256.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Behavioral outcomes not reported; the authors demonstrate</span></p>
<p style="top:247.3pt;left:266.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">the ability of endogenous cells to take up and retain the</span></p>
<p style="top:247.3pt;left:276.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">C3-transferase compound after SCI</span></p>
<p style="top:707.0pt;left:292.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Tanaka et al., 2004 [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt;color:#0000ff">58</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">]</span></p>
<p style="top:585.0pt;left:292.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rat</span></p>
<p style="top:534.8pt;left:292.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Thoracic hemisection</span></p>
<p style="top:401.2pt;left:292.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1) Y27632</span></p>
<p style="top:401.2pt;left:304.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2) Fasudil</span></p>
<p style="top:401.2pt;left:317.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">3) Cytoplasmic p21Cip1/WAF1</span></p>
<p style="top:392.7pt;left:327.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">fusion protein GST-</span><span style="font-family:AdvPSMP13,serif;font-size:8.5pt">D</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">NLS-p21-</span></p>
<p style="top:392.7pt;left:337.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">PTD-myc</span></p>
<p style="top:255.7pt;left:292.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">All agents increased neuronal sprouting and reduced cavity</span></p>
<p style="top:247.3pt;left:302.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">area; in addition, all compounds improved locomotor</span></p>
<p style="top:247.3pt;left:312.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">scores over control animals</span></p>
<p style="top:707.0pt;left:350.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Yamagishi et al., 2005 [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt;color:#0000ff">63</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">]</span></p>
<p style="top:585.0pt;left:350.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rat</span></p>
<p style="top:534.8pt;left:350.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Thoracic transection</span></p>
<p style="top:401.2pt;left:350.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1) Y-27632</span></p>
<p style="top:255.7pt;left:350.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Behavioral outcomes not reported; microtubule and</span></p>
<p style="top:247.3pt;left:360.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">neuro&#xfb01;lament breakdown was reduced with treatment</span></p>
<p style="top:707.0pt;left:373.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Chan et al., 2005 [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt;color:#0000ff">12</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">]</span></p>
<p style="top:585.0pt;left:373.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rat</span></p>
<p style="top:534.8pt;left:373.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Cervical dorsal column transection</span></p>
<p style="top:401.2pt;left:373.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1) Y-27632 (low dose compared</span></p>
<p style="top:392.7pt;left:383.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">with high dose)</span></p>
<p style="top:255.7pt;left:373.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Low-dose animals showed decreased sprouting in dorsal</span></p>
<p style="top:247.3pt;left:383.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">gray matter and had impaired locomoter recovery;</span></p>
<p style="top:247.3pt;left:393.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">high-dose-treated animals showed increased sprouting,</span></p>
<p style="top:247.3pt;left:402.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">increased distance of long axons, and improved</span></p>
<p style="top:247.3pt;left:412.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">locomotor recovery over controls</span></p>
<p style="top:707.0pt;left:425.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Nishio et al., 2006 [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt;color:#0000ff">46</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">]</span></p>
<p style="top:585.0pt;left:425.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rat</span></p>
<p style="top:534.8pt;left:425.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Thoracic impactor</span></p>
<p style="top:401.2pt;left:425.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1) Fasudil (immediate versus</span></p>
<p style="top:392.7pt;left:435.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">delayed treatment)</span></p>
<p style="top:255.7pt;left:425.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Immediate treatment resulted in increased sprouting and</span></p>
<p style="top:247.3pt;left:435.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">improved locomotor scores, whereas delayed treatment</span></p>
<p style="top:247.3pt;left:445.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">was not effective</span></p>
<p style="top:707.0pt;left:458.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Lord-Fontaine et al., 2008 [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt;color:#0000ff">38</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">]</span></p>
<p style="top:585.0pt;left:458.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rat/mouse</span></p>
<p style="top:534.8pt;left:458.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rat: thoracic impactor</span></p>
<p style="top:534.8pt;left:471.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Mouse: thoracic hemisection</span></p>
<p style="top:401.2pt;left:458.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1) BA-210 (Cethrin)</span></p>
<p style="top:255.7pt;left:458.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">BA-210 resulted in reduced lesion amount and increased</span></p>
<p style="top:247.3pt;left:468.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">spared white matter (only rat data reported); locomotor</span></p>
<p style="top:247.3pt;left:478.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">function was improved in both rat and mouse models;</span></p>
<p style="top:247.3pt;left:488.2pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">in addition, the authors report no development of</span></p>
<p style="top:247.3pt;left:498.2pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">mechanical allodynia</span></p>
<p style="top:707.0pt;left:514.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">SCI</span><span style="font-family:AdvTir_symb,serif;font-size:8.5pt"> =</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> spinal cord injury.</span></p>
<p style="top:33.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">736</span></p>
<p style="top:33.2pt;left:75.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Cadotte and Fehlings</span></p>
<p style="top:33.2pt;left:384.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Clinical Orthopaedics and Related Research</span><sup><span style="font-family:AdvPi3,serif;font-size:6.0pt">1</span></sup></p>
<p style="top:733.4pt;left:52.4pt;line-height:14.9pt"><span style="font-family:AdvSPRING,serif;font-size:14.9pt">123</span></p>


<p style="top:58.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">The de&#xfb01;nition of early surgery in the clinical context is</span></p>
<p style="top:70.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">open to interpretation, but most spinal surgeons would</span></p>
<p style="top:83.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">agree that early surgery is that which is undertaken within</span></p>
<p style="top:95.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">24 hours. In the paragraphs that follow, we review the</span></p>
<p style="top:108.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">evidence available for both preclinical and clinical studies.</span></p>
<p style="top:120.6pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">The majority of preclinical animal models stated that</span></p>
<p style="top:133.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">either the degree of compression (for example, the amount</span></p>
<p style="top:145.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of weight applied during a compression study) or the length</span></p>
<p style="top:157.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of time the spinal cord was compressed directly correlated</span></p>
<p style="top:170.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to the degree of recovery. Keeping in mind that these are</span></p>
<p style="top:182.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">animal experiments conducted under ideal circumstances,</span></p>
<p style="top:195.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">we review the preclinical literature with regard to the</span></p>
<p style="top:207.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">timing of decompression after traumatic SCI in the fol-</span></p>
<p style="top:220.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lowing three domains: (1) histopathologic correlation</span></p>
<p style="top:232.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">between the injury model and the damage caused to the</span></p>
<p style="top:245.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">spinal tissue; (2) animal models that did not show a func-</span></p>
<p style="top:257.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tional bene&#xfb01;t of early decompression; and (3) animal</span></p>
<p style="top:270.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">models</span></p>
<p style="top:270.0pt;left:88.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">that</span></p>
<p style="top:270.0pt;left:113.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">showed</span></p>
<p style="top:270.0pt;left:152.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">a</span></p>
<p style="top:270.0pt;left:165.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">functional</span></p>
<p style="top:270.0pt;left:215.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">bene&#xfb01;t</span></p>
<p style="top:270.0pt;left:251.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of</span></p>
<p style="top:270.0pt;left:269.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">early</span></p>
<p style="top:282.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">decompression.</span></p>
<p style="top:319.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Histopathologic Correlation</span></p>
<p style="top:344.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Three studies examined either the electrophysiological or</span></p>
<p style="top:357.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">histologic consequences of spinal cord compression with a</span></p>
<p style="top:369.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">&#xfb01;xed duration of time [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">4</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 6</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 34</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. The collective results of</span></p>
<p style="top:382.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">these early investigations into SCI suggest direct pressure</span></p>
<p style="top:394.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to the spinal cord, likely resulting in direct damage to the</span></p>
<p style="top:407.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neural cell membranes, combined with hypotension and</span></p>
<p style="top:419.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">resultant ischemia result in a loss of neurologic function.</span></p>
<p style="top:431.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Animals that showed recovery after injury demonstrated</span></p>
<p style="top:444.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">either a normal microscopic examination of the spinal cord</span></p>
<p style="top:456.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">or evidence of central gray necrosis, peripheral demyelin-</span></p>
<p style="top:469.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ization, or laceration. Animals that failed to recover</span></p>
<p style="top:481.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">showed more pronounced evidence of damage to the</span></p>
<p style="top:494.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neuroanatomic circuits of the spinal cord at the level of the</span></p>
<p style="top:506.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">anterior horn cells or laceration of either the gray or white</span></p>
<p style="top:519.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">matter.</span></p>
<p style="top:531.5pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Five studies failed to demonstrate a bene&#xfb01;t of early</span></p>
<p style="top:544.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">decompression after SCI. This generalized conclusion is</span></p>
<p style="top:556.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">closely linked to the experimental design of each of these</span></p>
<p style="top:568.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies. Of those that compared time of compression with</span></p>
<p style="top:581.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">outcome [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">1</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 17</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 61</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">], the maximum time of compression</span></p>
<p style="top:593.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">was 2 hours. To elaborate, Croft et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">17</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] showed that</span></p>
<p style="top:606.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with a graded pressure and time up to a maximum of 58 g</span></p>
<p style="top:618.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">for 20 minutes, the electrophysiological changes observed</span></p>
<p style="top:631.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(somatosensory-evoked potentials [SSEPs]) were com-</span></p>
<p style="top:643.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pletely reversible. The weakness of this investigation was</span></p>
<p style="top:656.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">that no statistical analysis was carried out. Thienprasit et al.</span></p>
<p style="top:668.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">[</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">61</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] subjected a group of cats to a compression model of</span></p>
<p style="top:680.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">SCI and then strati&#xfb01;ed the animals into those that demon-</span></p>
<p style="top:693.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">strated electrophysiological recovery within 6 hours and</span></p>
<p style="top:705.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">those that did not. Each group would then be strati&#xfb01;ed to</span></p>
<p style="top:58.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">receive decompression or decompression</span><span style="font-family:AdvTir_symb,serif;font-size:10.0pt"> +</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> hypothermia.</span></p>
<p style="top:70.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Of the animals that had electrophysiological recovery,</span></p>
<p style="top:83.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">there was no difference between the control group and the</span></p>
<p style="top:95.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">groups that received decompression or decompression</span><span style="font-family:AdvTir_symb,serif;font-size:10.0pt"> +</span></p>
<p style="top:108.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cooling. Of the animals that had no electrophysiological</span></p>
<p style="top:120.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">recovery, there was no difference between the control</span></p>
<p style="top:133.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">group and the group that received early decompression;</span></p>
<p style="top:145.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">however, the early decompression</span><span style="font-family:AdvTir_symb,serif;font-size:10.0pt"> +</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> cooling group did</span></p>
<p style="top:157.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">show better behavioral outcomes suggesting a possible</span></p>
<p style="top:170.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neuroprotective role for hypothermia after SCI. Aki and</span></p>
<p style="top:182.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Toya [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">1</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">], using a dog model, showed that compression for</span></p>
<p style="top:195.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">either 30 minutes or 60 minutes resulted in similar elec-</span></p>
<p style="top:207.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">trophysiological and histologic outcomes. The remaining</span></p>
<p style="top:220.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">two studies that failed to demonstrate a correlation between</span></p>
<p style="top:232.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the time of compression and outcome attempted to model</span></p>
<p style="top:245.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cauda equina injury [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">19</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] and studied a novel hydrogel [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">30</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]</span></p>
<p style="top:257.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with the hypothesis that this agent would act as a scaffold</span></p>
<p style="top:270.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">for neural repair after transection. Neither demonstrated an</span></p>
<p style="top:282.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">effect of early treatment.</span></p>
<p style="top:294.9pt;left:317.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">The number of animal studies that showed bene&#xfb01;t from</span></p>
<p style="top:307.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">early decompression far outweighed those that did not.</span></p>
<p style="top:319.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Using a primate model of SCI, Kobrine and others [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">35</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]</span></p>
<p style="top:332.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">showed that the duration of compression correlated to the</span></p>
<p style="top:344.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neurologic outcome of these animals and that physical</span></p>
<p style="top:357.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">injury to the neuronal membrane could account for a lack</span></p>
<p style="top:369.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of recovery. In a rat model that used &#xfb01;ve times as many</span></p>
<p style="top:382.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">animal subjects, Dolan et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">22</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] found the degree of</span></p>
<p style="top:394.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">functional recovery was directly proportional to the dura-</span></p>
<p style="top:406.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion and the force of compression whereby greater recovery</span></p>
<p style="top:419.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">was observed with lower forces and less time of com-</span></p>
<p style="top:431.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pression.</span></p>
<p style="top:431.9pt;left:351.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Guha</span></p>
<p style="top:431.9pt;left:381.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">et</span></p>
<p style="top:431.9pt;left:398.3pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">al.</span></p>
<p style="top:431.9pt;left:417.2pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">[</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">28</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]</span></p>
<p style="top:431.9pt;left:443.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">further</span></p>
<p style="top:431.9pt;left:479.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">delineated</span></p>
<p style="top:431.9pt;left:529.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">this</span></p>
<p style="top:444.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">observation using a rat model and concluded that the major</span></p>
<p style="top:456.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">determinant of recovery was the intensity of the compres-</span></p>
<p style="top:469.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sion and that the time of compression was important only</span></p>
<p style="top:481.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with lighter compressive forces. These results were echoed</span></p>
<p style="top:494.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">by a similar study conducted 1 year later [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">47</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. Zhang et al.</span></p>
<p style="top:506.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">[</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">64</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] expanded on this notion by measuring concentrations</span></p>
<p style="top:519.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of energy-related metabolites in the spinal cord after injury.</span></p>
<p style="top:531.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">They concluded that animals with a larger compressive</span></p>
<p style="top:544.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">force had higher concentrations of lactate and inosine in the</span></p>
<p style="top:556.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">extracellular compartment of the spinal cord and that these</span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">higher concentrations were associated with less neurologic</span></p>
<p style="top:581.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">recovery. Delamarter et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">18</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] used a canine model to</span></p>
<p style="top:593.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">show that compression of the cauda equina for 6 hours or</span></p>
<p style="top:606.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">longer resulted in a lack of motor recovery despite</span></p>
<p style="top:618.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">decompression. This lack of recovery was associated with</span></p>
<p style="top:631.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">central necrosis of the spinal cord. In a set of two experi-</span></p>
<p style="top:643.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ments using a canine model of SCI, Carlson et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">9</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 10</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]</span></p>
<p style="top:656.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">showed that the duration of compression could be corre-</span></p>
<p style="top:668.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lated to electrophysiology recordings and spinal cord blood</span></p>
<p style="top:681.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">&#xfb02;ow whereby a shorter duration of compression was</span></p>
<p style="top:693.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">associated with return of blood &#xfb02;ow and SSEP recovery.</span></p>
<p style="top:705.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Dimar et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">21</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] added the fact that longer duration of</span></p>
<p style="top:33.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Volume 469, Number 3, March 2011</span></p>
<p style="top:33.2pt;left:356.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">SCI: Treatment Options for Spinal Cord Injury</span></p>
<p style="top:33.2pt;left:531.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">737</span></p>
<p style="top:733.4pt;left:504.6pt;line-height:14.9pt"><span style="font-family:AdvSPRING,serif;font-size:14.9pt">123</span></p>


<p style="top:58.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">compression was associated with an extension of the injury</span></p>
<p style="top:70.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in a cephalad and caudal direction resulting in more pro-</span></p>
<p style="top:83.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">nounced cavitation and necrosis of the spinal cord. As</span></p>
<p style="top:95.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">technology improved, Carlson and others made use of MRI</span></p>
<p style="top:108.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to further our knowledge with regard to lesion volumes</span></p>
<p style="top:120.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">relative to the time of spinal compression [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">8</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. They dem-</span></p>
<p style="top:133.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">onstrated a difference in MRI-based lesion volumes</span></p>
<p style="top:145.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">between a 30-minute compression group and a 180-minute</span></p>
<p style="top:157.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">compression group. Perhaps the most hypothesis-driven</span></p>
<p style="top:170.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">study of recent times was carried out by Rabinowitz et al.</span></p>
<p style="top:182.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">[</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">50</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] who compared not only the timing of decompression,</span></p>
<p style="top:195.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">but also the use of methylprednisolone. Using a random-</span></p>
<p style="top:207.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ized design, the authors demonstrated dogs randomized to</span></p>
<p style="top:220.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">surgical decompression, with or without methylpredniso-</span></p>
<p style="top:232.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">lone administration, offers greater neurologic improvement</span></p>
<p style="top:245.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">than with the use of methylprednisolone alone. This is an</span></p>
<p style="top:257.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">important study that compared two therapies at the fore-</span></p>
<p style="top:270.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">front of human treatment that have yet been compared head</span></p>
<p style="top:282.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">to head. The authors rightfully comment on the value of</span></p>
<p style="top:294.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">such a trial. In summary, this collection of animal studies</span></p>
<p style="top:307.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">demonstrates a substantial body of evidence, across many</span></p>
<p style="top:319.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">species, that both the degree of initial force and the dura-</span></p>
<p style="top:332.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tion of compression are related to the degree of neurologic</span></p>
<p style="top:344.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">improvement.</span></p>
<p style="top:357.2pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">The neurologic outcomes after early decompressive</span></p>
<p style="top:369.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">surgery in clinical studies have been less promising than</span></p>
<p style="top:382.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">those in animal models. This is somewhat expected given</span></p>
<p style="top:394.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the dif&#xfb01;culty of controlling factors associated with acute</span></p>
<p style="top:407.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">injury in combination with an inherent rate of clinical</span></p>
<p style="top:419.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">improvement with proper medical management. Studies</span></p>
<p style="top:431.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">have therefore focused on the safety and feasibility of early</span></p>
<p style="top:444.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">surgery in addition to improvement in neurologic function.</span></p>
<p style="top:456.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">In the paragraphs that follow, we review the clinical evi-</span></p>
<p style="top:469.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">dence according to the level of evidence of each study. The</span></p>
<p style="top:481.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">methodological quality of the studies ranged from 7/32 to</span></p>
<p style="top:494.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">25/32 according to the criteria of Downs and Black [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">23</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">].</span></p>
<p style="top:506.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(Supplemental materials are available with the online</span></p>
<p style="top:519.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">version of CORR.)</span></p>
<p style="top:531.5pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">No Level I evidence exists to guide clinicians with</span></p>
<p style="top:544.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">regard to the timing of surgical decompression after SCI.</span></p>
<p style="top:556.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">We identi&#xfb01;ed two Level II studies [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">11</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 62</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. Vaccaro and</span></p>
<p style="top:568.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">others [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">62</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] studied 62 patients who presented with a spinal</span></p>
<p style="top:581.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">injury between C3 and T1. They de&#xfb01;ned the early surgery</span></p>
<p style="top:593.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">group as those who were treated within 72 hours and the</span></p>
<p style="top:606.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">late surgery group as those who were treated after 5 days.</span></p>
<p style="top:618.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">These authors found no difference between groups with</span></p>
<p style="top:631.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">regard to the length of stay in the intensive care unit or</span></p>
<p style="top:643.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">inpatient rehabilitation and no difference with regard to the</span></p>
<p style="top:656.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">American Spinal Injury Association (ASIA) motor score.</span></p>
<p style="top:668.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">In contrast, Cengiz et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">11</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] studied 27 patients who</span></p>
<p style="top:680.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">sustained a traumatic SCI from T8 to L2. They de&#xfb01;ned</span></p>
<p style="top:693.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">early surgery as that occurring within 8 hours of injury and</span></p>
<p style="top:705.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">late surgery as that occurring from 3 to 15 days after</span></p>
<p style="top:58.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">surgery. There were several differences between the groups</span></p>
<p style="top:70.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">at followup. The early surgery group showed more</span></p>
<p style="top:83.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">improvement on the ASIA Impairment Scale, no compli-</span></p>
<p style="top:95.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cations in-hospital, and a shorter length of stay both</span></p>
<p style="top:108.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in-hospital and in the intensive care unit (ICU). The later</span></p>
<p style="top:120.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">surgery group had four complications: three cases of lung</span></p>
<p style="top:133.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">failure and one case of sepsis. The authors concluded there</span></p>
<p style="top:145.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">are statistical differences between patients treated early and</span></p>
<p style="top:157.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">those treated late both with regard to neurologic improve-</span></p>
<p style="top:170.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ment and overall morbidity. There were no mortalities in</span></p>
<p style="top:182.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">either group. The majority of clinical studies that attempt to</span></p>
<p style="top:195.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">address the question of timing of decompression after</span></p>
<p style="top:207.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">traumatic SCI are Level III evidence. (Supplemental</span></p>
<p style="top:220.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">materials are available with the online version of CORR.)</span></p>
<p style="top:232.6pt;left:317.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Although space constraints prevent a detailed overview</span></p>
<p style="top:245.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of each study, we provide an overview of investigations</span></p>
<p style="top:257.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">that outline the following: (1) length of stay in the hospital;</span></p>
<p style="top:270.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(2) medical complications after SCI; and (3) neurologic</span></p>
<p style="top:282.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">outcome. We did not identify any Level IV evidence to</span></p>
<p style="top:294.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">guide clinicians with regard to the timing of surgical</span></p>
<p style="top:307.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">decompression after SCI.</span></p>
<p style="top:319.8pt;left:317.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">When attempting to study the effect of early surgery on</span></p>
<p style="top:332.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">SCI, a relatively easy metric to follow is the length of time</span></p>
<p style="top:344.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">a patient spends in the ICU or inpatient unit. This mea-</span></p>
<p style="top:357.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">surement considers not only the severity of injury, but also</span></p>
<p style="top:369.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the accessibility of the medical system at stabilizing the</span></p>
<p style="top:382.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">patient and allowing them to proceed with rehabilitation.</span></p>
<p style="top:394.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Of the 22 clinical studies identi&#xfb01;ed in this review, nine</span></p>
<p style="top:406.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Level III studies measured the length of stay [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">7</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 11</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 14</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 16</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span></p>
<p style="top:419.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">27</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 32</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 37</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 40</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 42</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 52</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. Early surgical decompression was</span></p>
<p style="top:431.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">associated with a shorter hospital length of stay in eight</span></p>
<p style="top:444.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studies [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">7</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 14</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 16</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 27</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 32</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 37</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 40</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 42</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] (although Guest et al.</span></p>
<p style="top:456.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">[</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">27</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] reported no p values), whereas the other only recorded</span></p>
<p style="top:469.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the length of stay in the ICU [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">52</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. A subset of these studies</span></p>
<p style="top:481.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">further divided overall length of stay with the duration of</span></p>
<p style="top:494.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">stay in the ICU [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">14</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 16</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 27</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 32</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] and found this time point</span></p>
<p style="top:506.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">was also less in patients receiving early decompressive</span></p>
<p style="top:519.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">surgery. Only one study [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">32</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] that measured these values</span></p>
<p style="top:531.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">found no correlation between timing of surgical decom-</span></p>
<p style="top:544.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pression and the length of stay in the ICU. An obvious</span></p>
<p style="top:556.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">extension to this measurement is the rate at which patients</span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">are readmitted to the hospital. This was measured in only</span></p>
<p style="top:581.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">one study [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">40</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] and the authors found no difference between</span></p>
<p style="top:593.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the early and late surgical intervention groups.</span></p>
<p style="top:606.2pt;left:317.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">The following complications were recorded in eight of</span></p>
<p style="top:618.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the 22 studies: respiratory care, wound infections, decubi-</span></p>
<p style="top:631.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">tus ulcers, cardiac complications, urinary tract infections,</span></p>
<p style="top:643.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">gastrointestinal hemorrhage, deep vein thrombosis (DVT),</span></p>
<p style="top:656.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and death. Four studies [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">7</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 36</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 37</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 41</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] reported no differ-</span></p>
<p style="top:668.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">ence in the rate of medical complications between the early</span></p>
<p style="top:681.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">and late surgical groups, whereas four studies found overall</span></p>
<p style="top:693.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">fewer complications in the persons receiving early surgical</span></p>
<p style="top:705.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">decompression. Speci&#xfb01;cally, Mirza et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">42</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] reported</span></p>
<p style="top:33.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">738</span></p>
<p style="top:33.2pt;left:75.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Cadotte and Fehlings</span></p>
<p style="top:33.2pt;left:384.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Clinical Orthopaedics and Related Research</span><sup><span style="font-family:AdvPi3,serif;font-size:6.0pt">1</span></sup></p>
<p style="top:733.4pt;left:52.4pt;line-height:14.9pt"><span style="font-family:AdvSPRING,serif;font-size:14.9pt">123</span></p>


<p style="top:58.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">fewer complications in persons receiving surgery within</span></p>
<p style="top:70.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">72 hours of injury; Croce et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">16</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] reported lower rates of</span></p>
<p style="top:83.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pneumonia and DVT in persons receiving surgery within</span></p>
<p style="top:95.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">24 hours; Chipman et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">14</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] reported a lower frequency of</span></p>
<p style="top:108.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">all complications in patients with an Injury Severity Score</span></p>
<p style="top:120.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(ISS) greater than 15 and receiving surgery within 72 hours</span></p>
<p style="top:133.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of injury (although this same group reports equal medical</span></p>
<p style="top:145.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">complications in persons with low ISS [less than 15]</span></p>
<p style="top:157.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">regardless of the time of decompression); McKinley et al.</span></p>
<p style="top:170.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">[</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">40</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] report higher rates of pneumonia in the late surgery</span></p>
<p style="top:182.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">group but equal rates of other complications (DVT, pul-</span></p>
<p style="top:195.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">monary embolism, ulcers).</span></p>
<p style="top:207.7pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">All studies reported whether or not patients recovered</span></p>
<p style="top:220.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neurologic function after surgical intervention and the</span></p>
<p style="top:232.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">majority (16 studies) attempted to compare the effect of</span></p>
<p style="top:245.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">early treatment on the timing of surgery. Four studies</span></p>
<p style="top:257.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">demonstrated early surgical decompression afforded better</span></p>
<p style="top:270.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neurologic outcomes: Clohisy et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">15</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] report surgical</span></p>
<p style="top:282.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">decompression within 48 hours resulted in improvement in</span></p>
<p style="top:294.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the modi&#xfb01;ed Frankel scale; McLain and Benson [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">41</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] report</span></p>
<p style="top:307.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">better neurologic improvement (no p value reported) with</span></p>
<p style="top:319.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">surgical decompression within 24 hours; Mirza et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">42</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]</span></p>
<p style="top:332.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">showed</span></p>
<p style="top:332.2pt;left:89.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">surgery</span></p>
<p style="top:332.2pt;left:127.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">within</span></p>
<p style="top:332.2pt;left:161.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">72</span></p>
<p style="top:332.2pt;left:179.6pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">hours</span></p>
<p style="top:332.2pt;left:209.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">resulted</span></p>
<p style="top:332.2pt;left:249.8pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in</span></p>
<p style="top:332.2pt;left:265.7pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">major</span></p>
<p style="top:344.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">improvements in the ASIA motor score, whereas surgery</span></p>
<p style="top:357.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">after 72 hours resulted in no improvement in the mean</span></p>
<p style="top:369.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">motor score; lastly, Papadopoulos et al. [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">48</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] found patients</span></p>
<p style="top:382.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">who received surgical decompression within 12 hours</span></p>
<p style="top:394.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(</span><span style="font-family:AdvTir_symb,serif;font-size:10.0pt">&#xb1;</span><span style="font-family:Times New Roman,serif;font-size:10.0pt"> 1.3 hours) had better neurologic improvement than</span></p>
<p style="top:407.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">those with surgery outside this time window. In a similar</span></p>
<p style="top:419.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">fashion, seven of the other studies with the same level of</span></p>
<p style="top:431.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">evidence reported no neurologic bene&#xfb01;t to early surgical</span></p>
<p style="top:444.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">decompression [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">13</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 16</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 27</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 37</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 40</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 49</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 51</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. Four studies</span></p>
<p style="top:456.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">showed equivocal results [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">5</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 25</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 36</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 59</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">].</span></p>
<p style="top:494.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Discussion</span></p>
<p style="top:519.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">An improved understanding of the secondary mechanisms</span></p>
<p style="top:531.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of SCI has resulted in novel strategies aimed at improving</span></p>
<p style="top:544.0pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">outcome for patients. In this review, we highlight three</span></p>
<p style="top:556.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">treatment strategies that have promise to demonstrate</span></p>
<p style="top:568.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">improved</span></p>
<p style="top:568.9pt;left:99.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">outcomes:</span></p>
<p style="top:568.9pt;left:149.9pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neuroprotection</span></p>
<p style="top:568.9pt;left:223.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">(riluzole),</span></p>
<p style="top:568.9pt;left:272.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Rho</span></p>
<p style="top:581.3pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">antagonists (Cethrin and other compounds), and early</span></p>
<p style="top:593.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">surgical decompression. We formulated speci&#xfb01;c questions</span></p>
<p style="top:606.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">for each and systematically reviewed the literature to</span></p>
<p style="top:618.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">answer these questions.</span></p>
<p style="top:631.1pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">There are two main limitations to this systematic review.</span></p>
<p style="top:643.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">The &#xfb01;rst is we searched only the English language. Without</span></p>
<p style="top:656.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">access to scienti&#xfb01;c work published in other parts of the</span></p>
<p style="top:668.5pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">world we cannot be certain that the most important work in</span></p>
<p style="top:680.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the &#xfb01;elds of riluzole, Cethrin, or early surgical decom-</span></p>
<p style="top:693.4pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">pression has been reviewed. The second limitation of this</span></p>
<p style="top:705.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">work is the inherent bias of preselecting three treatment</span></p>
<p style="top:58.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">strategies for a condition in which many more are being</span></p>
<p style="top:70.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">studied. We chose to systematically review riluzole,</span></p>
<p style="top:83.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Cethrin, and early surgical decompression because these</span></p>
<p style="top:95.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">treatment strategies are at a point in their development</span></p>
<p style="top:108.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">where large clinical trials are either being planned or are</span></p>
<p style="top:120.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">underway. The aim of this work is to bring clinicians up to</span></p>
<p style="top:133.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">date on works that will likely affect patients with SCI over</span></p>
<p style="top:145.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">the next several years.</span></p>
<p style="top:157.9pt;left:317.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Studies involving the neuroprotective agent riluzole</span></p>
<p style="top:170.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">focus on local tissue protection, functional neurologic</span></p>
<p style="top:182.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">recovery, and a single study on spasticity. There has not</span></p>
<p style="top:195.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">been a dose&#x2013;response study for the application of riluzole</span></p>
<p style="top:207.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in the setting of SCI, but the agent is FDA-approved for use</span></p>
<p style="top:220.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in the setting of ALS. Based on the available preclinical</span></p>
<p style="top:232.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">evidence, riluzole has moved into human clinical trials</span></p>
<p style="top:245.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">under the direction of the North American Clinical Trials</span></p>
<p style="top:257.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Network.</span></p>
<p style="top:270.0pt;left:317.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Rho antagonists have been studied in rat and mouse</span></p>
<p style="top:282.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">models of SCI. Only one animal study involved the cer-</span></p>
<p style="top:294.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">vical spine; all others involved the thoracic spine. A</span></p>
<p style="top:307.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">number of compounds exist that are directly applied to the</span></p>
<p style="top:319.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">spinal cord after injury. Detailed dosing studies and the</span></p>
<p style="top:332.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">establishment of a therapeutic window of application have</span></p>
<p style="top:344.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">not been conducted. The commercial form of Rho antag-</span></p>
<p style="top:357.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">onist is termed Cethrin; this agent is currently undergoing a</span></p>
<p style="top:369.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">human clinical trial.</span></p>
<p style="top:382.1pt;left:317.5pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Early surgical decompression is playing an increasing</span></p>
<p style="top:394.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">role in the treatment of acute SCI. Although still contro-</span></p>
<p style="top:406.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">versial, evidence is mounting for its safety, clinical, and</span></p>
<p style="top:419.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">neurologic outcomes. The de&#xfb01;nition of early surgery is not</span></p>
<p style="top:431.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">&#xfb01;xed, but most consider early to be less than 24 hours. In</span></p>
<p style="top:444.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">terms of safety, the treating surgeon must balance the</span></p>
<p style="top:456.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">potential bene&#xfb01;ts of early surgery versus the risk. The</span></p>
<p style="top:469.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">bene&#xfb01;ts include relieving cord compression and therefore</span></p>
<p style="top:481.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">limiting secondary injury. The risks include aggravating</span></p>
<p style="top:494.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">secondary injury by hypotensive episodes or blood loss.</span></p>
<p style="top:506.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Several studies point out that patients should be treated</span></p>
<p style="top:519.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">with early surgery if medically stable to do so [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">2</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 11</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">].</span></p>
<p style="top:531.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Clinical bene&#xfb01;ts of early surgery possibly include shorter</span></p>
<p style="top:544.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">length of both ICU and overall hospital stay with fewer</span></p>
<p style="top:556.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">medical complications (such as pneumonia and DVT) [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">60</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">].</span></p>
<p style="top:568.9pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">This claim has been challenged by other studies. In terms</span></p>
<p style="top:581.3pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">of neurologic outcome, the &#xfb01;eld of SCI research is torn</span></p>
<p style="top:593.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">between substantive evidence from preclinical animal</span></p>
<p style="top:606.2pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">models favoring early surgery [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">29</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 31</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">,</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff"> 48</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">] and mixed</span></p>
<p style="top:618.7pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">evidence from human clinical trials. Recent preliminary</span></p>
<p style="top:631.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">results from the Surgical Treatment for Acute Spinal Cord</span></p>
<p style="top:643.6pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">Injury Study (STASCIS) suggest decompression of the</span></p>
<p style="top:656.1pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">spinal cord within 24 hours of injury is associated with</span></p>
<p style="top:668.5pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">improved neurologic recovery in persons with cervical</span></p>
<p style="top:681.0pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">injury [</span><span style="font-family:Times New Roman,serif;font-size:10.0pt;color:#0000ff">45</span><span style="font-family:Times New Roman,serif;font-size:10.0pt">]. A &#xfb01;nal report from this multicenter prospective</span></p>
<p style="top:693.4pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">cohort study is expected within the next year after long-</span></p>
<p style="top:705.8pt;left:306.1pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">term followup is complete.</span></p>
<p style="top:33.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Volume 469, Number 3, March 2011</span></p>
<p style="top:33.2pt;left:356.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">SCI: Treatment Options for Spinal Cord Injury</span></p>
<p style="top:33.2pt;left:531.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">739</span></p>
<p style="top:733.4pt;left:504.6pt;line-height:14.9pt"><span style="font-family:AdvSPRING,serif;font-size:14.9pt">123</span></p>


<p style="top:58.3pt;left:62.4pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">This systematic review presents some of the recent ideas</span></p>
<p style="top:70.8pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">in SCI research and how these have translated into both</span></p>
<p style="top:83.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">clinical trials of biologic compounds and clinical practice.</span></p>
<p style="top:95.7pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">With continued research at the basic science and clinical</span></p>
<p style="top:108.1pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">levels, new strategies will surely evolve to optimize care of</span></p>
<p style="top:120.6pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">this devastating condition.</span></p>
<p style="top:164.2pt;left:51.0pt;line-height:10.0pt"><span style="font-family:Times New Roman,serif;font-size:10.0pt">References</span></p>
<p style="top:187.9pt;left:55.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1. Aki T, Toya S. Experimental study on changes of the spinal-</span></p>
<p style="top:197.8pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">evoked potential and circulatory dynamics following spinal cord</span></p>
<p style="top:207.8pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">compression and decompression.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Spine</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1984;9:800&#x2013;809.</span></p>
<p style="top:217.7pt;left:55.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2. Albin MS, White RJ. Epidemiology, physiopathology, and</span></p>
<p style="top:227.7pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">experimental therapeutics of acute spinal cord injury.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Crit Care</span></p>
<p style="top:237.6pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Clin</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1987;3:441&#x2013;452.</span></p>
<p style="top:247.6pt;left:55.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">3. Ates O, Cayli SR, Gurses I, Turkoz Y, Tarim O, Cakir CO, Kocak</span></p>
<p style="top:257.6pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">A. Comparative neuroprotective effect of sodium channel</span></p>
<p style="top:267.5pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">blockers after experimental spinal cord injury.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Clin Neurosci</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">.</span></p>
<p style="top:277.5pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2007;14:658&#x2013;665.</span></p>
<p style="top:287.5pt;left:55.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">4. Bohlman HH, Bahniuk E, Raskulinecz G, Field G. Mechanical</span></p>
<p style="top:297.4pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">factors affecting recovery from incomplete cervical spinal cord</span></p>
<p style="top:307.4pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">injury: a preliminary report.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Johns Hopkins Med J</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1979;145:</span></p>
<p style="top:317.3pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">115&#x2013;125.</span></p>
<p style="top:327.3pt;left:55.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">5. Botel U, Glaser E, Niedeggen A. The surgical treatment of acute</span></p>
<p style="top:337.3pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">spinal paralysed patients.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Spinal Cord</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1997;35:420&#x2013;428.</span></p>
<p style="top:347.2pt;left:55.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">6. Brodkey JS, Richards DE, Blasingame JP, Nulsen FE. Reversible</span></p>
<p style="top:357.2pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">spinal cord trauma in cats. Additive effects of direct pressure and</span></p>
<p style="top:367.2pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">ischemia.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Neurosurg</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1972;37:591&#x2013;593.</span></p>
<p style="top:377.1pt;left:55.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">7. Campagnolo DI, Esquieres RE, Kopacz KJ. Effect of timing of</span></p>
<p style="top:387.1pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">stabilization on length of stay and medical complications fol-</span></p>
<p style="top:397.1pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">lowing spinal cord injury.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Spinal Cord Med</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1997;20:331&#x2013;334.</span></p>
<p style="top:407.0pt;left:55.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">8. Carlson GD, Gorden CD, Oliff HS, Pillai JJ, LaManna JC. Sus-</span></p>
<p style="top:417.0pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">tained spinal cord compression: part I: time-dependent effect on</span></p>
<p style="top:426.9pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">long-term pathophysiology.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Bone Joint Surg Am</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 2003;85:</span></p>
<p style="top:436.9pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">86&#x2013;94.</span></p>
<p style="top:446.9pt;left:55.3pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">9. Carlson GD, Minato Y, Okada A, Gorden CD, Warden KE,</span></p>
<p style="top:456.8pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Barbeau JM, Biro CL, Bahnuik E, Bohlman HH, Lamanna JC.</span></p>
<p style="top:466.8pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Early time-dependent decompression for spinal cord injury:</span></p>
<p style="top:476.8pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">vascular mechanisms of recovery.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Neurotrauma</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1997;14:</span></p>
<p style="top:486.7pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">951&#x2013;962.</span></p>
<p style="top:496.7pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">10. Carlson GD, Warden KE, Barbeau JM, Bahniuk E, Kutina-Nel-</span></p>
<p style="top:506.6pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">son KL, Biro CL, Bohlman HH, LaManna JC. Viscoelastic</span></p>
<p style="top:516.6pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">relaxation and regional blood &#xfb02;ow response to spinal cord com-</span></p>
<p style="top:526.5pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">pression and decompression.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Spine</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1997;22:1285&#x2013;1291.</span></p>
<p style="top:536.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">11. Cengiz SL, Kalkan E, Bayir A, Ilik K, Basefer A. Timing of</span></p>
<p style="top:546.5pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">thoracolomber spine stabilization in trauma patients; impact on</span></p>
<p style="top:556.5pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">neurological outcome and clinical course. A real prospective (rct)</span></p>
<p style="top:566.4pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">randomized</span></p>
<p style="top:566.4pt;left:112.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">controlled</span></p>
<p style="top:566.4pt;left:154.4pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">study.</span></p>
<p style="top:566.4pt;left:182.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Arch</span></p>
<p style="top:566.4pt;left:205.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Orthop</span></p>
<p style="top:566.4pt;left:237.2pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Trauma</span></p>
<p style="top:566.4pt;left:271.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Surg</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">.</span></p>
<p style="top:576.4pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2008;128:959&#x2013;966.</span></p>
<p style="top:586.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">12. Chan CC, Khodarahmi K, Liu J, Sutherland D, Oschipok LW,</span></p>
<p style="top:596.3pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Steeves JD, Tetzlaff W. Dose-dependent bene&#xfb01;cial and detri-</span></p>
<p style="top:606.3pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">mental effects of ROCK inhibitor Y27632 on axonal sprouting</span></p>
<p style="top:616.2pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">and functional recovery after rat spinal cord injury.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Exp Neurol</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">.</span></p>
<p style="top:626.2pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2005;196:352&#x2013;364.</span></p>
<p style="top:636.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">13. Chen L, Yang H, Yang T, Xu Y, Bao Z, Tang T. Effectiveness of</span></p>
<p style="top:646.1pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">surgical treatment for traumatic central cord syndrome.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Neu-</span></p>
<p style="top:656.1pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">rosurg Spine</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 2009;10:3&#x2013;8.</span></p>
<p style="top:666.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">14. Chipman JG, Deuser WE, Beilman GJ. Early surgery for thora-</span></p>
<p style="top:676.0pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">columbar spine injuries decreases complications.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Trauma</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">.</span></p>
<p style="top:686.0pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2004;56:52&#x2013;57.</span></p>
<p style="top:695.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">15. Clohisy JC, Akbarnia BA, Bucholz RD, Burkus JK, Backer RJ.</span></p>
<p style="top:705.9pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Neurologic recovery associated with anterior decompression of</span></p>
<p style="top:58.3pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">spine fractures at the thoracolumbar junction (T12-L1).</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Spine</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">.</span></p>
<p style="top:68.2pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1992;17:S325&#x2013;330.</span></p>
<p style="top:78.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">16. Croce MA, Bee TK, Pritchard E, Miller PR, Fabian TC. Does</span></p>
<p style="top:88.1pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">optimal timing for spine fracture &#xfb01;xation exist?</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Ann Surg</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">.</span></p>
<p style="top:98.1pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2001;233:851&#x2013;858.</span></p>
<p style="top:108.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">17. Croft TJ, Brodkey JS, Nulsen FE. Reversible spinal cord trauma:</span></p>
<p style="top:118.0pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">a model for electrical monitoring of spinal cord function.</span></p>
<p style="top:128.0pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">J Neurosurg</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1972;36:402&#x2013;406.</span></p>
<p style="top:137.9pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">18. Delamarter RB, Sherman J, Carr JB. Pathophysiology of spinal</span></p>
<p style="top:147.9pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">cord injury. Recovery after immediate and delayed decompres-</span></p>
<p style="top:157.9pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">sion.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Bone Joint Surg Am</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1995;77:1042&#x2013;1049.</span></p>
<p style="top:167.8pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">19. Delamarter RB, Sherman JE, Carr JB. 1991 Volvo Award in</span></p>
<p style="top:177.8pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">experimental</span></p>
<p style="top:177.8pt;left:372.5pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">studies.</span></p>
<p style="top:177.8pt;left:405.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Cauda</span></p>
<p style="top:177.8pt;left:434.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">equina</span></p>
<p style="top:177.8pt;left:464.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">syndrome:</span></p>
<p style="top:177.8pt;left:507.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">neurologic</span></p>
<p style="top:187.7pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">recovery following immediate, early, or late decompression.</span></p>
<p style="top:197.7pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Spine</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1991;16:1022&#x2013;1029.</span></p>
<p style="top:207.7pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">20. Dergham P, Ellezam B, Essagian C, Avedissian H, Lubell WD,</span></p>
<p style="top:217.6pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">McKerracher L. Rho signaling pathway targeted to promote</span></p>
<p style="top:227.6pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">spinal cord repair.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Neurosci</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 2002;22:6570&#x2013;6577.</span></p>
<p style="top:237.6pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">21. Dimar JR 2nd, Glassman SD, Raque GH, Zhang YP, Shields CB.</span></p>
<p style="top:247.5pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">The in&#xfb02;uence of spinal canal narrowing and timing of decom-</span></p>
<p style="top:257.5pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">pression on neurologic recovery after spinal cord contusion in a</span></p>
<p style="top:267.4pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">rat model.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Spine</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1999;24:1623&#x2013;1633.</span></p>
<p style="top:277.4pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">22. Dolan EJ, Tator CH, Endrenyi L. The value of decompression for</span></p>
<p style="top:287.3pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">acute experimental spinal cord compression injury.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Neurosurg</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">.</span></p>
<p style="top:297.3pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1980;53:749&#x2013;755.</span></p>
<p style="top:307.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">23. Downs SH, Black N. The feasibility of creating a checklist for the</span></p>
<p style="top:317.3pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">assessment of the methodological quality both of randomised and</span></p>
<p style="top:327.2pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">non-randomised studies of health care interventions.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Epidemiol</span></p>
<p style="top:337.2pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Community Health</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1998;52:377&#x2013;384.</span></p>
<p style="top:347.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">24. Dubreuil CI, Winton MJ, McKerracher L. Rho activation patterns</span></p>
<p style="top:357.1pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">after spinal cord injury and the role of activated Rho in apoptosis</span></p>
<p style="top:367.1pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">in the central nervous system.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Cell Biol</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 2003;162:233&#x2013;243.</span></p>
<p style="top:377.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">25. Duh MS, Shepard MJ, Wilberger JE, Bracken MB. The effec-</span></p>
<p style="top:387.0pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">tiveness of surgery on the treatment of acute spinal cord injury</span></p>
<p style="top:396.9pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">and its relation to pharmacological treatment.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Neurosurgery</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">.</span></p>
<p style="top:406.9pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1994;35:240&#x2013;248; discussion 248&#x2013;249.</span></p>
<p style="top:416.9pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">26. Fournier AE, Takizawa BT, Strittmatter SM. Rho kinase inhibi-</span></p>
<p style="top:426.9pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">tion enhances axonal regeneration in the injured CNS.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Neurosci</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">.</span></p>
<p style="top:436.8pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2003;23:1416&#x2013;1423.</span></p>
<p style="top:446.8pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">27. Guest J, Eleraky MA, Apostolides PJ, Dickman CA, Sonntag VK.</span></p>
<p style="top:456.7pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Traumatic central cord syndrome: results of surgical manage-</span></p>
<p style="top:466.7pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">ment.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Neurosurg</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 2002;97:25&#x2013;32.</span></p>
<p style="top:476.6pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">28. Guha A, Tator CH, Endrenyi L, Piper I. Decompression of the</span></p>
<p style="top:486.6pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">spinal cord improves recovery after acute experimental spinal</span></p>
<p style="top:496.6pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">cord compression injury.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Paraplegia</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1987;25:324&#x2013;339.</span></p>
<p style="top:506.5pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">29. Harvey C, Wilson SE, Greene CG, Berkowitz M, Stripling TE.</span></p>
<p style="top:516.5pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">New estimates of the direct costs of traumatic spinal cord</span></p>
<p style="top:526.5pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">injuries: results of a nationwide survey.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Paraplegia</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1992;30:</span></p>
<p style="top:536.5pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">834&#x2013;850.</span></p>
<p style="top:546.4pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">30. Hejcl A, Urdzikova L, Sedy J, Lesny P, Pradny M, Michalek J,</span></p>
<p style="top:556.4pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Burian M, Hajek M, Zamecnik J, Jendelova P, Sykova E. Acute</span></p>
<p style="top:566.3pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">and delayed implantation of positively charged 2-hydroxyethyl</span></p>
<p style="top:576.3pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">methacrylate scaffolds in spinal cord injury in the rat.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Neuro-</span></p>
<p style="top:586.2pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">surg Spine</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 2008;8:67&#x2013;73.</span></p>
<p style="top:596.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">31. Kakulas BA. Neuropathology: the foundation for new treatments</span></p>
<p style="top:606.2pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">in spinal cord injury.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Spinal Cord</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 2004;42:549&#x2013;563.</span></p>
<p style="top:616.1pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">32. Kerwin AJ, Frykberg ER, Schinco MA, Griffen MM, Murphy T,</span></p>
<p style="top:626.1pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Tepas JJ. The effect of early spine &#xfb01;xation on non-neurologic</span></p>
<p style="top:636.1pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">outcome.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Trauma</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 2005;58:15&#x2013;21.</span></p>
<p style="top:646.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">33. Kitzman PH. Effectiveness of riluzole in suppressing spasticity in</span></p>
<p style="top:656.0pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">the spinal cord injured rat.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Neurosci Lett</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 2009;455:150&#x2013;153.</span></p>
<p style="top:665.9pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">34. Kobrine AI, Evans DE, Rizzoli H. Correlation of spinal cord</span></p>
<p style="top:675.9pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">blood &#xfb02;ow and function in experimental compression.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Surg</span></p>
<p style="top:685.9pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Neurol</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1978;10:54&#x2013;59.</span></p>
<p style="top:695.8pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">35. Kobrine AI, Evans DE, Rizzoli HV. Experimental acute balloon</span></p>
<p style="top:705.8pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">compression of the spinal cord. Factors affecting disappearance</span></p>
<p style="top:33.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">740</span></p>
<p style="top:33.2pt;left:75.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Cadotte and Fehlings</span></p>
<p style="top:33.2pt;left:384.9pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Clinical Orthopaedics and Related Research</span><sup><span style="font-family:AdvPi3,serif;font-size:6.0pt">1</span></sup></p>
<p style="top:733.4pt;left:52.4pt;line-height:14.9pt"><span style="font-family:AdvSPRING,serif;font-size:14.9pt">123</span></p>


<p style="top:58.3pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">and return of the spinal evoked response.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Neurosurg</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1979;51:</span></p>
<p style="top:68.2pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">841&#x2013;845.</span></p>
<p style="top:78.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">36. Krengel WF 3rd, Anderson PA, Henley MB. Early stabilization</span></p>
<p style="top:88.1pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">and decompression for incomplete paraplegia due to a thoracic-</span></p>
<p style="top:98.1pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">level spinal cord injury.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Spine</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1993;18:2080&#x2013;2087.</span></p>
<p style="top:108.0pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">37. Levi L, Wolf A, Rigamonti D, Ragheb J, Mirvis S, Robinson WL.</span></p>
<p style="top:118.0pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Anterior decompression in cervical spine trauma: does the timing</span></p>
<p style="top:128.0pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">of surgery affect the outcome?</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Neurosurgery</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1991;29:216&#x2013;222.</span></p>
<p style="top:137.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">38. Lord-Fontaine S, Yang F, Diep Q, Dergham P, Munzer S,</span></p>
<p style="top:147.9pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Tremblay P, McKerracher L. Local inhibition of Rho signaling by</span></p>
<p style="top:157.9pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">cell-permeable recombinant protein BA-210 prevents secondary</span></p>
<p style="top:167.8pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">damage and promotes functional recovery following acute spinal</span></p>
<p style="top:177.8pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">cord injury.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Neurotrauma</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 2008;25:1309&#x2013;1322.</span></p>
<p style="top:187.7pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">39. McAdoo DJ, Hughes MG, Nie L, Shah B, Clifton C, Fullwood S,</span></p>
<p style="top:197.7pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Hulsebosch CE. The effect of glutamate receptor blockers on</span></p>
<p style="top:207.7pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">glutamate release following spinal cord injury. Lack of evidence</span></p>
<p style="top:217.6pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">for an ongoing feedback cascade of damage &#x2013;</span><span style="font-family:AdvPSMP4,serif;font-size:8.5pt"> [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> glutamate</span></p>
<p style="top:227.6pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">release &#x2013;</span><span style="font-family:AdvPSMP4,serif;font-size:8.5pt"> [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> damage &#x2013;</span><span style="font-family:AdvPSMP4,serif;font-size:8.5pt"> [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> glutamate release &#x2013;</span><span style="font-family:AdvPSMP4,serif;font-size:8.5pt"> [</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> etc.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Brain Res.</span></p>
<p style="top:237.6pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2005;1038:92&#x2013;99.</span></p>
<p style="top:247.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">40. McKinley W, Meade MA, Kirshblum S, Barnard B. Outcomes of</span></p>
<p style="top:257.5pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">early surgical management versus late or no surgical intervention</span></p>
<p style="top:267.5pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">after acute spinal cord injury.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Arch Phys Med Rehabil</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 2004;85:</span></p>
<p style="top:277.4pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1818&#x2013;1825.</span></p>
<p style="top:287.4pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">41. McLain RF, Benson DR. Urgent surgical stabilization of spinal</span></p>
<p style="top:297.3pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">fractures in polytrauma patients.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Spine</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1999;24:1646&#x2013;1654.</span></p>
<p style="top:307.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">42. Mirza SK, Krengel WF 3rd, Chapman JR, Anderson PA, Bailey</span></p>
<p style="top:317.3pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">JC, Grady MS, Yuan HA. Early versus delayed surgery for acute</span></p>
<p style="top:327.2pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">cervical spinal cord injury.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Clin Orthop Relat Res</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1999;104&#x2013;114.</span></p>
<p style="top:337.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">43. Mu X, Azbill RD, Springer JE. Riluzole and methylprednisolone</span></p>
<p style="top:347.2pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">combined treatment improves functional recovery in traumatic</span></p>
<p style="top:357.1pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">spinal cord injury.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Neurotrauma</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 2000;17:773&#x2013;780.</span></p>
<p style="top:367.1pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">44. Mu X, Azbill RD, Springer JE. Riluzole improves measures of</span></p>
<p style="top:377.0pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">oxidative stress following traumatic spinal cord injury.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Brain Res</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">.</span></p>
<p style="top:387.0pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2000;870:66&#x2013;72.</span></p>
<p style="top:396.9pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">45. Ng WP, Fehlings MG, Cuddy B, Dickman C, Fazl M, Green B,</span></p>
<p style="top:406.9pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Hitchon P, Northrup B, Sonntag V, Wagner F, Tator CH. Surgical</span></p>
<p style="top:416.9pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">treatment for acute spinal cord injury study pilot study #2:</span></p>
<p style="top:426.9pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">evaluation of protocol for decompressive surgery within 8 hours</span></p>
<p style="top:436.8pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">of injury.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Neurosurg Focus</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1999;6:e3.</span></p>
<p style="top:446.8pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">46. Nishio Y, Koda M, Kitajo K, Seto M, Hata K, Taniguchi J,</span></p>
<p style="top:456.8pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Moriya H, Fujitani M, Kubo T, Yamashita T. Delayed treatment</span></p>
<p style="top:466.7pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">with Rho-kinase inhibitor does not enhance axonal regeneration</span></p>
<p style="top:476.7pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">or functional recovery after spinal cord injury in rats.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Exp Neurol</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">.</span></p>
<p style="top:486.6pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2006;200:392&#x2013;397.</span></p>
<p style="top:496.6pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">47. Nystrom B, Berglund JE. Spinal cord restitution following</span></p>
<p style="top:506.5pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">compression injuries in rats.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Acta Neurol Scand</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1988;78:</span></p>
<p style="top:516.5pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">467&#x2013;472.</span></p>
<p style="top:526.5pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">48. Papadopoulos SM, Selden NR, Quint DJ, Patel N, Gillespie B,</span></p>
<p style="top:536.5pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Grube S. Immediate spinal cord decompression for cervical</span></p>
<p style="top:546.4pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">spinal cord injury: feasibility and outcome.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Trauma</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 2002;52:</span></p>
<p style="top:556.4pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">323&#x2013;332.</span></p>
<p style="top:566.3pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">49. Pollard ME, Apple DF. Factors associated with improved neu-</span></p>
<p style="top:576.3pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">rologic outcomes in patients with incomplete tetraplegia.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Spine</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">.</span></p>
<p style="top:586.2pt;left:65.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">2003;28:33&#x2013;39.</span></p>
<p style="top:58.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">50. Rabinowitz RS, Eck JC, Harper CM Jr, Larson DR, Jimenez MA,</span></p>
<p style="top:68.2pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Parisi JE, Friedman JA, Yaszemski MJ, Currier BL. Urgent</span></p>
<p style="top:78.2pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">surgical decompression compared to methylprednisolone for the</span></p>
<p style="top:88.1pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">treatment of acute spinal cord injury: a randomized prospective</span></p>
<p style="top:98.1pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">study in beagle dogs.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Spine</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> (Phila Pa 1976). 2008;33:2260&#x2013;2268.</span></p>
<p style="top:108.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">51. Sapkas GS, Papadakis SA. Neurological outcome following early</span></p>
<p style="top:118.0pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">versus delayed lower cervical spine surgery.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Orthop Surg</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> (Hong</span></p>
<p style="top:128.0pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Kong). 2007;15:183&#x2013;186.</span></p>
<p style="top:137.9pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">52. Schinkel C, Frangen TM, Kmetic A, Andress HJ, Muhr G.</span></p>
<p style="top:147.9pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Timing of thoracic spine stabilization in trauma patients: impact</span></p>
<p style="top:157.9pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">on clinical course and outcome.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Trauma</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 2006;61:156&#x2013;160;</span></p>
<p style="top:167.8pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">discussion 160.</span></p>
<p style="top:177.8pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">53. Schwartz G, Fehlings MG. Evaluation of the neuroprotective</span></p>
<p style="top:187.7pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">effects of sodium channel blockers after spinal cord injury:</span></p>
<p style="top:197.7pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">improved behavioral and neuroanatomical recovery with riluzole.</span></p>
<p style="top:207.7pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">J Neurosurg</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 2001;94:245&#x2013;256.</span></p>
<p style="top:217.6pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">54. Sekhon LH, Fehlings MG. Epidemiology, demographics, and</span></p>
<p style="top:227.6pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">pathophysiology of acute spinal cord injury.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Spine</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> (Phila Pa</span></p>
<p style="top:237.6pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1976). 2001;26:S2&#x2013;12.</span></p>
<p style="top:247.5pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">55. Springer JE, Azbill RD, Kennedy SE, George J, Geddes JW.</span></p>
<p style="top:257.5pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Rapid calpain I activation and cytoskeletal protein degradation</span></p>
<p style="top:267.4pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">following traumatic spinal cord injury: attenuation with riluzole</span></p>
<p style="top:277.4pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">pretreatment.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Neurochem</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1997;69:1592&#x2013;1600.</span></p>
<p style="top:287.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">56. Stutzmann JM, Pratt J, Boraud T, Gross C. The effect of riluzole</span></p>
<p style="top:297.3pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">on post-traumatic spinal cord injury in the rat.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Neuroreport</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">.</span></p>
<p style="top:307.3pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1996;7:387&#x2013;392.</span></p>
<p style="top:317.3pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">57. Sung JK, Miao L, Calvert JW, Huang L, Louis Harkey H, Zhang</span></p>
<p style="top:327.2pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">JH. A possible role of RhoA/Rho-kinase in experimental spinal</span></p>
<p style="top:337.2pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">cord injury in rat.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Brain Res</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 2003;959:29&#x2013;38.</span></p>
<p style="top:347.2pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">58. Tanaka H, Yamashita T, Yachi K, Fujiwara T, Yoshikawa H,</span></p>
<p style="top:357.1pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Tohyama M. Cytoplasmic p21(Cip1/WAF1) enhances axonal</span></p>
<p style="top:367.1pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">regeneration and functional recovery after spinal cord injury in</span></p>
<p style="top:377.0pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">rats.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Neuroscience</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 2004;127:155&#x2013;164.</span></p>
<p style="top:387.0pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">59. Tator CH, Fehlings MG, Thorpe K, Taylor W. Current use and</span></p>
<p style="top:396.9pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">timing of spinal surgery for management of acute spinal surgery for</span></p>
<p style="top:406.9pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">management of acute spinal cord injury in North America: results</span></p>
<p style="top:416.9pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">of a retrospective multicenter study.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Neurosurg</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1999;91:12&#x2013;18.</span></p>
<p style="top:426.9pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">60. Tator CH, Koyanagi I. Vascular mechanisms in the pathophysi-</span></p>
<p style="top:436.8pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">ology of human spinal cord injury.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Neurosurg</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 1997;86:483&#x2013;</span></p>
<p style="top:446.8pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">492.</span></p>
<p style="top:456.8pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">61. Thienprasit P, Bantli H, Bloedel JR, Chou SN. Effect of delayed</span></p>
<p style="top:466.7pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">local cooling on experimental spinal cord injury.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Neurosurg</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">.</span></p>
<p style="top:476.6pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1975;42:150&#x2013;154.</span></p>
<p style="top:486.6pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">62. Vaccaro AR, Daugherty RJ, Sheehan TP, Dante SJ, Cotler JM,</span></p>
<p style="top:496.6pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Balderston RA, Herbison GJ, Northrup BE. Neurologic outcome</span></p>
<p style="top:506.5pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">of early versus late surgery for cervical spinal cord injury.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Spine</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">.</span></p>
<p style="top:516.5pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1997;22:2609&#x2013;2613.</span></p>
<p style="top:526.5pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">63. Yamagishi S, Fujitani M, Hata K, Kitajo K, Mimura F, Abe H,</span></p>
<p style="top:536.5pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Yamashita T. Wallerian degeneration involves Rho/Rho-kinase</span></p>
<p style="top:546.4pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">signaling.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> J Biol Chem</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">. 2005;280:20384&#x2013;20388.</span></p>
<p style="top:556.4pt;left:306.1pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">64. Zhang Y, Hillered L, Olsson Y, Holtz A. Time course of energy</span></p>
<p style="top:566.3pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">perturbation after compression trauma to the spinal cord: an</span></p>
<p style="top:576.3pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">experimental study in the rat using microdialysis.</span><span style="font-family:Times New Roman,serif;font-size:8.5pt"> Surg Neurol</span><span style="font-family:Times New Roman,serif;font-size:8.5pt">.</span></p>
<p style="top:586.2pt;left:320.7pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">1993;39:297&#x2013;304.</span></p>
<p style="top:33.2pt;left:51.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">Volume 469, Number 3, March 2011</span></p>
<p style="top:33.2pt;left:356.0pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">SCI: Treatment Options for Spinal Cord Injury</span></p>
<p style="top:33.2pt;left:531.6pt;line-height:8.5pt"><span style="font-family:Times New Roman,serif;font-size:8.5pt">741</span></p>
<p style="top:733.4pt;left:504.6pt;line-height:14.9pt"><span style="font-family:AdvSPRING,serif;font-size:14.9pt">123</span></p>

</div>
